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Summary 
Cancer is a disease that imposes a heavy burden on public health and poses a challenge to 
science. The World Health Organization estimates that 80% of people in developing 
countries of the world rely on traditional medicine for their primary health needs, and about 
85% of traditional medicine involves the use of plant extracts. This is particularly true in 
Africa where a large percentage of the population depends upon medicinal plants for health 
care. Therefore, detailed screening and evaluation of bioactive substances for 
chemotherapeutic purposes of African plants are urgently warranted. Furthermore, this will 
serve to validate the efficacy and safety of African traditional medicine.  
The current study investigated the in vitro cytotoxic effects of 17 ethanolic extracts of the 
following 16 plants used in traditional anticancer medicine in Nigeria: Sapium ellipticum 
leaves, Sapium ellipticum  stembark, Combretum paniculatum, Celosia trigyna, Pupalia 
lappacea, Justica extensa, Hedranthera barteri leaves, Alternanthera sessilis, Ethulia 
conyzoides leaves, Lannea nigritana stembark, Combretum zenkeri root, Combretum molle 
leaves, Adenanthera parvoniana, Lannea acida, Cyathula achyranthoides, Drymaria 
cordata, Cyathula prostrata, against HeLa cancer cells.  Five of the most promising extracts 
(Sapium ellipticum leaves, Combretum paniculatum, Celosia trigyna, Drymaria cordata, 
Cyathula prostrata) were selected for further screening against HT29 and MCF-7 cancer 
cells. Of the five, the first two were investigated further based on their activities in the 
screening phase.   
The S. ellipticum leaf extract yielded IC50 values of 88.60 ± 0.03 and 93.03 ± 0.03 μg/ml 
against HeLa and MCF-7, respectively.  The toxicity was also evaluated on normal cells and 
an IC50 of 77.66 µg/ml was obtained for peripheral blood mononuclear cells (PBMCs).  The 
IC50 values for proliferating and confluent Chang liver cells were both >125 µg/ml.  These 
results suggest that the extract may be selective for specific cell types.    
Bio-assay guided fractionation of the S. ellipticum ethanolic extract yielded two active 
fractions; chloroform and ethyl acetate. Two compounds isolated from the chloroform extract 
were screened against the three cancer cell lines and found to be inactive.  Three compounds 
were isolated from the ethyl acetate fraction and revealed IC50 values < 62.5 and < 31 μg/ml 
against MCF-7. Unfortunately these two compounds soon lost activity before any further 
work could be done on them and work was continued with the crude extract. 
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Cell cycle analysis with propidium iodide staining revealed that S. ellipticum leaf crude 
extract has a dual effect, inducing G1/G0 and G2/M arrest of HeLa, HT29 and MCF-7 cells 
after 48 hours. Using the Annexin V-FITC/PI assay, the plant extract was found not to cause 
an increase in apoptosis when compared to the vehicle control cells. These results conclude 
that S. ellipticum does not cause apoptosis but acts as an inhibitor of proliferation. 
Due to C. paniculatum’s potential cytotoxicity, the leaf crude extract was further fractionated 
into three fractions. All three were active against the three cancer cell lines with the highest 
activity seen in the ethyl acetate fraction. Two pure compounds with a dose-dependent 
cytotoxic effect were isolated from the ethyl acetate fraction and identified as pheophorbide a 
(Cpe 4-4), and pheophorbide a methyl ester (Cpe 3-4).  Pheophorbide a and pheophorbide a 
methyl ester had comparable activities against HeLa and MCF-7 cells but the former was 
more active on HT29 cells. It was also more cytotoxic to normal PBMCs and cell cycle 
analysis results revealed that 62.5 μg/ml of the methyl ester was a more potent inducer of cell 
cycle arrest in G1/G0 phase. No increase was observed in the sub-G1 (apoptotic) peak for any 
of the two compounds and it would appear that reduction in viable cell numbers compared to 
control cells is due to inhibition of proliferation rather than cytotoxicity. 
A frequent characteristic of cancer cells is elevated telomerase activity which overrides 
normal replicative senescence due to telomere shortening. Telomerase inhibition is an 
attractive anticancer target and U937 cells were used to investigate possible effects of the 17 
plant extracts on the levels of the catalytic subunit of telomerase (hTERT). Seven of the plant 
extracts gave promising results when levels of hTERT protein were lower than the control 
cells at 12.5 and 125 µg/ml after 48 hours of exposure.  S. ellipticum showed a decrease in the 
level of hTERT protein at the higher concentration at both 24 and 48 hours.  By quantifying 
one or more reference proteins in the same cells in which hTERT levels were measured, one 
would be able to validate the results and observe any possible non-target effects. β-actin and 
GAPDH were included as reference proteins but neither gave satisfactory results.  
Finally, three more extracts (Uvaria chamae and Lecaniodiscus cupanioides leaf (LL) and 
root extracts (LR) were screened for cytotoxic activity as part of an ongoing collaboration 
with the University of Lagos. U. chamae showed low activity against HT29 but >50% 
inhibition against HeLa and MCF-7 at 125 μg/ml. LR showed very low inhibitory effect 
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against all three cancer cell lines. LL was active and an ethyl acetate fraction was found to 
hold the best promise for future investigation.  
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Chapter 1: Literature review 
1.1 Cancer today 
Cancer, often believed to be a disease of the so called developed world, has become a global 
health challenge [1]. It is the second largest cause of death world-wide [2, 3] after heart 
disease [4] and the incidence of cancer is increasing rapidly all over the world [1]. Increase in 
population size as well as continuing, globalization trends, are instrumental in the global 
increase of cancer [1]. Cancer has a profound toll on human suffering, with substantial 
economic cost to society [2]. A total of 559 888 cancer deaths were recorded in the United 
States in 2006, accounting for about 23% of all deaths [5]. In 1997, a world-wide total of 6.2 
million deaths were due to cancer (out of a total of 52.2 million deaths).  Cancers of the lung 
(1.1 million), stomach (765 00), colon and rectum (525 000), liver (505 000), and breast 
(385 000) were the leading cause of deaths from cancer [6]. 
What is cancer and how is it defined? For many people cancer was a death sentence, but 
today it is a curable disease for some and a chronic illness for most [7]. At first it was 
believed that cancer arise when cell growth exceeds the rate at which cells die, so that the 
cells grow at an uncontrollable rate [8]. However cancer is now being described as the 
product of malfunctions within the regulation of the cell cycle. These malfunctions thus allow 
injured or mutated cells which are normally killed to progress through the cell cycle, 
accumulating mutations [9]. 
Cancer is a disease that involves dynamic changes in the genome. It is a multistep process 
characterized by a progression of changes on cellular and genetic level leading to the 
uncontrolled growth of abnormal cells within the body [10]. These cells can also acquire the 
ability to invade surrounding normal tissue boundaries and metastasize to distant organs [11]. 
During normal growth and differentiation, cell proliferation is strictly controlled to maintain 
homeostasis [12]. Homeostasis within a cell is regulated by the balance between proliferation, 
growth arrest and apoptosis [9]. During cancer development the genomes of the cancer cells 
acquire mutant alleles of proto-oncogenes, tumour suppressor genes and other genes that 
control cell proliferation [13]. 
What then are the proto-oncogenes and the tumor suppressor genes? During the 1970s, 
scientists discovered two families of genes that play major roles in the genesis and spread of 
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cancer, namely the oncogenes and tumor suppressor genes [4]. Proto-oncogenes are 
regulatory genes that code for proteins that function to drive the cell cycle forward [14, 15]. 
These proteins play a central role in receiving and processing of growth-stimulating signals 
from the extracellular environment. The growth-stimulating signals bind to their receptors on 
the cell surface. The receptors convey a stimulatory signal to proteins in the cytoplasm to the 
nucleus where transcription is initiated to generate proteins that will move the cell through its 
growth cycle [15, 16]. 
Oncogenes, the mutated form of proto-oncogenes, cause the proteins involved in these 
growth-promoting pathways to be overactive [16]. Oncogenes behave in a dominant way, 
whereby one of the two alleles of the genes needs to be altered for a biological effect to occur 
[13]. In contrast to proto-oncogenes and oncogenes that code for growth-stimulating proteins, 
tumour suppressor genes code for inhibitory proteins that normally act to prevent cell growth 
or even promote programmed cell death (apoptosis) [13,17]. These genes are recessive; both 
alleles must be mutated before an effect is seen [13].  
Apart from the coordination action of proto-oncogenes and tumor-suppressor genes cells 
have at least three other systems that can help them avoid runaway cell division. They have a 
DNA repair system, detecting and correcting errors in DNA. Should this system fail, the error 
(now a mutation) becomes a permanent feature in that cell and its descendants. A second 
cellular back-up system prompts the cell to commit suicide (apoptosis) if damaged beyond 
repair. This observation suggests that tumours arise from cells that have managed to evade 
apoptosis. A third back-up system limits the number of times a cell can divide [15]. The ends 
of chromosomes are capped with a protective DNA sequence (telomeres). These telomeres 
progressively become shorter after each cycle of cell division. When telomeres reach a 
threshold length an internal signal is triggered, that causes the cell to stop dividing [18].   
Cancer cells have the ability to activate cell growth independent from growth stimuli due to 
mutations of intracellular signal pathways [9]. Research has revealed a small number of 
molecular, biochemical, and cellular traits - acquired capabilities - shared by most cancers 
[10]. The classical features of most cancer cell genotypes are their capacity to generate their 
own mutagenic signal, their insensitivity to anti-growth signals, evasion of apoptosis, ability 
to proliferate without limits, sustained angiogenesis and invasion and metastatic properties [7, 
19, 20]. 
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The majority of human cancers result from exposure to environmental carcinogens [3]. A 
minority of cancers are known to be hereditary [6]. Possible causes of the malfunctions 
within the regulation of the cell cycle are viruses, chemical carcinogens, chromosomal 
rearrangements, spontaneous transformations, oncogenes and tumour suppressor genes [3]. 
Since cancer is being described as a malfunction within the regulation of the cell cycle, the 
next section will give an overview of the function and regulation of the cell cycle. 
 
1.2 The cell cycle 
The cell cycle is a highly ordered and tightly regulated process that results in the duplication 
and transmission of genetic information from one cell generation to the next [21]. It is a 
sequence of events by which a growing cell duplicates its components and divides them into 
two nearly identical daughter cells, so that each daughter cell receives all the genetic 
information to repeat the process [22]. In order to replicate, a cell must first produce DNA, 
secondly manufacture sufficient cellular organelles and all that is needed for cell duplication. 
Finally, equal partition of the DNA and cytoplasm must occur to form two daughter cells [3]. 
The cell cycle process begins with a stimulus, which is the release of growth factors from 
neighbouring cells. These factors bind to receptors on the cell membrane. The binding of 
ligands stimulates a series of events inside the cell where the signals are conveyed to 
cytoplasmic proteins, which in turn signal the release of transcription factors within the 
nucleus. These signal transductions push the cell through the cell cycle [9]. To ensure that the 
molecular events are sequential and correctly orientated a significant amount of feedback 
control is in place. Failure to control the cell cycle carries with it a high price [3]. 
Morphologically the cell cycle can be subdivided into the interphase and mitotic (M) phase 
(Figure 1.1). The M phase includes prophase, metaphase, anaphase and telophase. The 
interphase includes the first gap phase (G1), synthesis phase (S) and the second gap phase 
(G2) [23, 24]. 
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Figure 1.1: The stages of the cell cycle. The cell cycle can be subdivided into the interphase (G1, S and G2) and 
the mitotic phase (prophase, metaphase, anaphase and telophase) [25]. 
 
1.2.1 Interphase 
Interphase describes the phase in the cell cycle where there is active preparation for cell 
division. Most adult mammals spend 90% of the total time of cell division in this phase [26]. 
There are three stages of interphase in which cells that are committed to replication; they 
move from G1 (first stage) into S phase (second stage) and finally into G2 (third phase) 
before duplication in the M phase [9]. 
 
1.2.1.1 G0 phase 
The daughter cells from the previous cycle can either transit to the quiescent state, where they 
can remain in G0 indefinitely or return to the G1 phase of the cell cycle upon appropriate 
stimulation [27]. Quiescent cells are viable cells found in the G0 phase of the cell cycle 
where there is minimal protein synthesis. A cell may remain in this state for many years, but 
can re-enter the cell cycle at G1, following binding of a growth factor to the extracellular 
receptor [28]. 
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1.2.1.2 G1 phase 
During G1 phase a decision is made either to proliferate or enter G0 [27]. During this phase a 
cell is subject to stimulation by extracellular growth factors and mitogens. In response to 
these stimuli the cell passes through G1 [21]. G1 represents a phase in which a cell 
synthesizes a series of mRNAs and proteins that are necessary for DNA synthesis in the S 
phase [28]. 
1.2.1.3  S phase  
The S phase involves duplication of the entire genome [29]. This phase is of particular 
importance, because replication of chromosomes and segregation (M phase) ensures that each 
daughter cell receives a full complement of hereditary material [30]. 
1.2.1.4 G2 phase 
The G2 phase represents a time where there is active protein synthesis and preparation for 
mitosis [29]. During this phase cells can repair errors that occurred during DNA duplication, 
preventing propagation of these errors to daughter cells [31]. 
 
1.2.2 Mitotic phase 
Mitosis involves five phases, based on the state of the chromosomes and spindles. 
Cytokinesis is the final physical cell division that follows telophase [32]. M phase is marked 
by the generation of bipolar mitotic spindles, segregation of sister chromatids and cell 
division [21]. 
 
1.3 Cell cycle regulation 
To ensure survival and propagation of accurate copies of the genome on to subsequent 
generations, control mechanisms are in place to avoid inappropriate cell proliferation [33, 
34]. Different cellular proteins regulate the transition from one cell cycle phase to another. 
Cyclin–dependent kinases (CDKs), a family of serine/threonine protein kinases are the key 
regulatory proteins which are activated at specific points of the cell cycle [24]. CDKs form 
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distinct complexes with cyclin proteins at specific phases of the cell cycle (Figure 1.2) and 
thereby drive the cell from one stage of the cell cycle to another [28]. CDK 1, 2, 4 and 6 seem 
to be important players in cell cycle control. CDK1 is responsible for initiating mitosis at the 
G2/M transition. CDK 2, 4 and 6 are involved in passage through the restriction point and 
consequent initiation of S phase [27].  
 
 
 
CDK protein levels remain stable during the cell cycle, in contrast to their activating proteins, 
the cyclins [24]. Cyclins perform multiple regulatory functions [23] and activated 
cyclin/CDK complexes function during distinct stages of the cell cycle (Table 1.1) [21]. 
Cyclin A and B contain a destruction box and cyclins D and E contain a PEST sequence 
(segment rich in proline (P), glutamic acid (E), serine (S) and threonine (T) residues): these 
are protein sequences required for efficient ubiquitin-mediated cyclin proteolysis at the end of 
a cycle phase [23, 24]. Within each phase of the cell cycle the level of cyclins independently 
increase or decrease due to regulated degradation [21]. Thus, before a cell enters the next 
phase, the appropriate cyclin of the previous phase is degraded and the cyclin of the next 
phase synthesized [23].  The D type cyclins (D1, D2 and D3) bind to CDK 4 and to CDK 6, 
and mediate the progression through G1 [24, 33]. Cyclin D is synthesized as long as the 
growth stimuli persist [24]. Cycin E associates with CDK2 to regulate progression from G1 
into S phase [24, 31, 35]. Cyclin B in complex with CDK1 further regulates mitosis [24]. 
Cyclins B contain nuclear localization signals (NLS) that target the CDKs to the nucleus. 
Figure 1.2: The cell cycle and cyclins. The site of activity of regulatory cyclin/CDK complexes is also indicated. 
[24] 
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These nuclear localization signals are lacking in CDKs [24]. Cyclin A gets activated during 
the S phase transition and binds to CDK1 and CDK2 [33, 35]. Once bound to the CDKs, the 
cyclins are able to guide the CDKs to appropriate substrates and activate catalytic activity 
[36].  
 
CAK, CDK activating kinase                   [24]
  
The positive regulatory activities of the cyclins and CDK on the cell cycle are constrained by 
CDK inhibitors (CKIs) [28]. CKIs have been assigned to one of two families (Table 1.2) 
based on their structures and CDK targets [37]. They can be divided into the INK4 proteins, 
which specifically inhibit the catalytic subunits of CDK 4 and CDK 6 and the Cip/Kip 
proteins whose actions affect the activities of cyclin D-, E-, and A-dependent kinases [24, 
28].  
There are four INK4 family members: p16
INK4a
, p15
INK4b
, p19
 INK4d
, and p18
INK4c
, which 
specifically inactivate CDK 4 and CDK 6 in the G1 phase. These CKIs form stable 
complexes with the CDK enzyme, before cyclin binding, preventing association with cyclin 
D.  
The Cip/Kip family members include: p21
Waf/Cip1
, p27
Kip1
, and p57
Kip2
. These inhibitors 
inactivate CDK-cyclin complexes. Thus, CKIs can bind to CDK alone or to the CDK-cyclin 
complex and regulate CDK activity [24, 37]. By binding to and inhibiting the proliferating 
cell nuclear antigen (PCNA), p21 inhibits DNA synthesis. The expression of p21 is under 
CDK 
 
Cyclin Cell cycle phase activity 
CDK 1 Cyclin D1, D2, D3 G1 phase 
CDK 6 Cyclin D1, D2, D3 G1 phase 
CDK 2 Cyclin E G1/S phase transition 
CDK2 Cyclin A S phase 
CDK 1                   (cdc2) Cyclin A G2/M phase transition 
CDK 1                   (cdc2) Cyclin B Mitosis 
CDK 7 Cyclin H CAK, all cell cycle phases 
Table 1.1: Cyclin CDK complexes are activated at specific points of the cell cycle. 
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transcriptional control of p53 tumour suppressor gene. Activation of p15 and p27, contributes 
to growth arrest in response to transforming growth factor β (TGY-β). CDK inactivating 
kinases Wee1 and Myt 1 protect the cell from premature mitosis and 14-3-3 group of proteins 
regulates the intracellular trafficking of different proteins [24]. 
 
 
CKI family Function Family members  
INK4 family Inactivation P15 (INK4b) 
Of G1 CDK P16 (INK4a) 
(CDK4, CDK6) P18 (INK4c) 
 P19 (INK4d) 
Cip/Kip family Inactivation of P21 (Waf1, Cip1) 
G1 cyclin-CDK P27 (Cip2) 
Complexes and P57 (Kip2) 
Cyclin B-CDK1   
                   [24] 
 
1.4 Cell cycle progression 
Cell cycle progression is an organized process that controls cell growth, cell proliferation, 
and ontogenesis and is well connected to the regulation of DNA damage repair [33]. It 
requires a series of phosphorylation and dephosphorylation events carried out by protein 
kinases and phosphatases [38]. Multiple mechanisms exist to regulate the progression of the 
cell cycle after its initiation (Figure 1.3) [27]. During the G1 phase cells respond to 
extracellular growth or mitogenic stimulation that ultimately determine whether cells will 
make the decision to replicate DNA and divide, or alternately, exit the cell cycle into a 
quiescent state (G0) [39]. Stimulation by growth factors or mitogenic factors to enter the cell 
cycle from G0 to G1 phase  requires continuous mitogenic stimulation during the first two-
thirds of G1 phase  to be driven to the “restriction point” R  [36, 39, 40]. There is an increase 
in the expression of the D cyclins (D1, D2 and D3) as the cell moves out of G0 into G1 [21]. 
Once synthesized, the D-type cyclins associate with CDK 4 and CDK 6 [40]. Formation of 
Table 1.2: Cyclin dependent kinase inhibitors (CKI) bind to CDK alone or to the CDK-cyclin 
complex and regulate CDK activity. P19 (ARF) is also encoded by the INK 4 locus, but has no 
known CKI acitivity 
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the cyclin-CDK complexes results in the phosphorylation of CDKs whereby activated CDKs, 
phosporylate the retinoblastoma (Rb) protein [21]. Phophorylation of pRb by CDK 4/6 leads 
to disruption of the complex with histone deacetylase (HDAC) and the release of the 
transcription factor E2F-1 and DP-1 allowing E2F to transcribe a number of responder genes 
required for passage through R [21, 23, 24]. pRb is maintained in its hyperphosphorylated 
state throughout the remainder of the cell cycle and cyclin E/CDK 2 participates in 
maintaining this hyperphosphorylated state [24].  
 
 
Figure 1.3: The cell cycle. The cell cycle is divided into four phases (G1, S, G2, and M). Progression through 
the cell cycle is promoted by cyclin-dependent kinases (CDKs), which are regulated positively by cyclins and 
negatively by CDK inhibitors (CDKIs). The restriction point is the point at which cells progress through the cell 
cycle independent of external stimuli [35]. 
 
 
pRb is the gatekeeper of the cell cycle (Figure 1.4). As the cell progresses through late G1, 
cyclin E increases. Transition from G1 to S phase requires the cyclin E/CDK 2 complex [21]. 
The latter complex phosphorylates its inhibitor p27; inducing its proteasome-dependent 
degradation [24]. Increased expression of cyclin A occurs at G1/S transition and persists 
through S phase. DNA synthesis proceeds through binding of cyclin A to CDK 2. Increase of 
cyclin A and cyclin B complexes with CDK 1 allows progression of the cell through mitosis 
[21]. 
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Figure 1.4: Rb and cell cycle machinery. Rb and Rb-p represent the unphosphorylated and the phosphorylated 
forms of the retinoblastoma protein. In G0 and early G1, Rb physically associates with E2F factors and blocks 
their transactivation domain. In late G1, Rb-p releases E2F, allowing the expression of genes that encode 
product necessary for S-phase progression [36].  
 
1.5 Cell cycle checkpoints and cell cycle arrest 
Under normal circumstances the cell cycle proceeds without interruptions. However, most 
normal cells have the capacity to arrest proliferation when damage occurs in G1, S and G2 of 
the cell cycle, and then resume when the damage has been repaired [41]. The arrest or delay 
of the cell cycle progression is mediated by a network of signalling pathways, the quality 
control points of the cell cycle referred to as checkpoints [34, 42]. When checkpoints are 
activated they relay signals to the cell cycle progression machinery, which in turn cause a 
delay in cell cycle progression, until the danger of the mutation has been rectified [43]. 
Checkpoints are biochemical signalling pathways that sense various types of structural 
defects in DNA, or chromosome activities and induce a multifaceted cellular response that 
activates DNA repair and delays cell cycle progression. Potentially hazardous cells with 
irreparable DNA damage are eliminated by checkpoints through permanent cell cycle arrest 
or cell death [44].  
Cell cycle checkpoints mediate cell cycle arrest which is produced by a variety of factors that 
may be intrinsic or extrinsic and may affect several different checkpoints [23]. Cell cycle 
arrest is essential because it allows time to repair damage before DNA synthesis [45]. 
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Checkpoints are activated by under replicated DNA, damaged DNA or faulty mitotic spindle 
alignment and these signals are relayed to the cell cycle progression machinery [33, 41]. 
Arrest in G1 allows time for repairs before DNA replication whereas arrest in G2 allows time 
for repairs before chromosome separation in mitosis [23].  
The biochemical pathways that delay progression, or transition between major cell cycle 
phases are discussed in the next sections [34]. 
 
1.5.1 The restriction point 
The G1/S transition is a highly regulated and important transition in the cell cycle [42]. The 
point of no return, following which a cell is committed to enter the cell cycle, is defined as 
the restriction point (R) [24]. This is a critical point late in G1 phase where mammalian cells 
make the decision to begin DNA replication, becoming committed to entering the S phase 
and to completing the cell cycle even in the absence of growth factors [39, 42]. Evidence that 
has been accumulated over the past twelve to fifteen years has shown that the Retinoblastoma 
protein pRb is the molecular device that serves as the R point switch [36, 40, 46].  Cyclin 
D/CDK 4/6 complex initiates pRb phosphorylation. Subsequent phosphorylation of pRb 
occurs at the hand of cyclin E/CDK 2 complexes. The formation of cyclin E/CDK 2 complex 
in late G1 phase acts as a positive feedback loop on the pRb pathway already initiated by 
cyclin D/CDK 4 [42] 
 
1.5.2 G1 checkpoint and G1 arrest 
During G1, cells make critical decision about their fate. They check whether their 
environment favours proliferation and whether their genome is ready to be replicated [47]. 
Damage of the genome occurring during the G1 phase of the cell cycle causes rapid cell cycle 
arrest [40]. Arrest in response to DNA damage in the G1 phase of the cell cycle has been 
found to depend heavily on the action of p53 a product of a tumour suppressor gene, which is 
known to be mutated in more than 50% of human cancers [41]. DNA damage activates the 
checkpoint transducing kinasesmataxia-telangiectasia-mutated/ataxia and rad3 related 
(ATM/ATR) and DNA protein kinase (DNA PK) family of protein kinases which leads to the 
post-translational stabilisation of normally labile p53 protein [24, 40]. Induced p53 acts as a 
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transcription regulatory factor that causes the expression of several responder genes, 
including p21, growth arrest and DNA damage inducible gene (GADD45) and Murine 
Double Minute-2 (Mdm2). It can also act as a transcriptional repressor by interfering with the 
binding of basal transcription factors to the TATA motif which may account for some of the 
ability of p53 to interfere with neoplastic processes [41, 48]. Accumulation of p21, results in 
the inhibition of cyclin E/CDK2 and cyclin D/CDK 4/6 complexes and hypophosphorylation 
of pRb [47]. Another important regulator of the G1/S cyclin/CDK complexes is p16, known 
to inhibit cyclin D/CDK 4/6 complexes probably acting as an inhibitor of pRb 
phosphorylation [41]. p21 mediates p53-dependent G1 arrest by inhibiting the activity of 
CDKs, which phosphorylate the pRB. In its hypophosphorylated form pRB sequester the E2F 
transcription factor, preventing transition from G1 to S phase [49].  
  
1.5.3 S phase checkpoint and S phase arrest 
Less is known about the S phase DNA checkpoint [24, 48]. It serves to protect the genome 
from spontaneous damage during replication [50] and operates like a surveillance camera 
[51]. Stalled replication forks that are processed to Holiday junctions and double-strand 
breaks are one source of spontaneous damage. Checkpoint activation caused by DNA damage 
or stalled replication forks inhibit ongoing DNA synthesis, giving time for DNA repair [50]. 
The G1/S, S and G2/M checkpoints share some components. ATR, the primary S phase 
checkpoint kinase, plays a role in both damage sensing and DNA replication [52]. It gets 
activated by stalled replication forks (caused by hydroxyurea (HU)) and lesions (caused by 
ultraviolet (UV) light) [50]. In contrast to ATR, ATM only sense DNA double–strand breaks 
caused by ionizing radiation [50, 52]. Many S phase checkpoint genes, such as ATM, 
Nijmegen Breakage Syndrome gene (NBSI), Meiotic recombinant 11 homolog A (Mre11), 
Breast Cancer 1, Early Onset gene (BRCA 1), Chk 2 and Fanconi Anemia Complement 
Group D2 (FANCD 2) are mutated in human cancers [50]. 
 
1.5.4 The G2/M checkpoint and G2/M arrest 
To ensure accurate segregation of chromosomes, cells in G2 phase of the cell cycle prevent 
mitosis in the presence of DNA damage [34, 53]. Signal transduction cascades link the 
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detection of DNA breaks to inhibition of CDK 1, and thus to the inhibition of mitosis, the 
induction of DNA repair and of apoptosis [54]. CDK 1 is maintained in its inhibited form, 
through inhibitory phosphorylation or by sequestration of components of the cyclin B/CDK 1 
complex outside the nucleus [24]. Thus, regulation of cyclin B/CDK1 complex involves 
activating phosphate by CDK-activating enzyme and inhibitory phosphates in the roof of the 
active site by Wee 1 [53]. Agents that trigger the G2 checkpoint response suppress cyclin 
B/CDK 1 activation at the G2/M border [41]. After DNA damage, activation of cyclin 
B/CDK 1 is prevented through ATM/ATR and Chk1/Chk2 inhibition or Cdc25c phosphatase 
that normally activates Cdk1 at the G2/M border [34]. p53 also plays a role in the regulation 
of the G2/M checkpoint. DNA damage dependent increase of p53 leads to an increase of p21 
and of 14-3-3 σ. p53 also mediates the dissociation of cyclin B/CDK1 complexes by 
induction of GADD45 [24, 34].  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
1.5.5 Mitotic spindle checkpoint and arrest 
The spindle checkpoint is a specific checkpoint that arrests cells in mitosis (anaphase) until 
all chromosomes is attached properly to the spindle [41, 55]. It is activated by a lack of 
attachment and/or tension at kinetochores and in response inhibits chromosome segregation 
[56]. It serves to inhibit cell cycle progression until all chromosomes are appropriately bound 
to microtubules at their kinetochores. Kinetochore attachment is recognized as a key 
regulator of initiation of mitosis. A single unattached kinetochore is sufficient to inhibit 
mitosis [27]. Progression through mitosis is dependent on the degradation of cyciln B on the 
anaphase-promoting complex (APC)/cyclosome [35, 41]. The assembly of the bipolar spindle 
by the centrosome is vital to the prevention of genetic infidelity between daughter cells [35]. 
Mitotic arrest deficient (Mad) and budding uninhibited by benomyl (Bub) proteins are 
activated when defects in microtubule attachment occur and inhibit the Cdc 20 subunit of the 
APC resulting in the prevention of metaphase-anaphase transition [24]. 
One theme emerging in drug discovery is to develop agents that target the cell cycle 
checkpoint that is responsible for the control of cell cycle progression [53]. 
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1.6 Apoptosis and necrosis 
1.6.1 Apoptosis 
Fundamental aspects of the life cycle of a eukaryotic cell are cell growth, differentiation and 
cell death [57]. Programmed cell death involves genetically determined elimination of cells 
which is an important aspect of organism development through its role in maintaining a 
balance between cell growth and death [58]. Apoptosis is a form of programmed cell death 
which enables an organism to eliminate old, unwanted and abnormal cells through an orderly 
process of cellular disintegration that avoids eliciting inflammation [59, 60]. It plays an 
essential role in controlling cell number in many developmental and physiological settings 
[61].  
Kerr and colleagues (1972) proposed the term apoptosis which described a specific 
morphological pattern of cell death observed as cells were eliminated during embryonic 
development, normal cell turn over in healthy adult tissue, and atrophy upon hormone 
withdrawal [60]. Its morphological characteristics include chromatin condensation, nuclear 
fragmentation, plasma membrane blebbing and cell shrinkage. Ultimately there is the 
formation of apoptotic bodies (small membrane surrounded fragments) that are phagocytosed 
without inflicting an inflammatory response (Figure 1.5) [58, 60, 62, 63].  This is achieved by 
an energy- and caspase dependent phosphatidylserine (PS) exposure on the outer leaflet of 
the plasma membrane [60].  
The exposure of PS is a biochemical feature that results in early phagocytic recognition by 
adjacent cells, resulting in quick phagocytosis with minimal compromise to surrounding 
tissue [58]. Collapse of the membrane lipid asymmetry, [64] leads to the expression of 
negatively charged PS from the inner to the outer cell membrane [58, 60, 65]. In healthy cells 
PS is localized on the inner leaflet of the plasma membrane [60]. Annexin V is a PS-binding 
protein that interacts strongly and specifically with PS residues and can be used for the 
detection of apoptosis [58] via flow cytometry when fluorescently conjugated [60]. In vitro, 
apoptotic bodies may lose their integrity and proceed to secondary apoptotic necrosis due to 
absence of phagocytosis [60]. 
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Figure 1.5: Hallmarks of the apoptotic and necrotic cell death process. Apoptosis includes cellular shrinking, 
chromatin condensation and margination at the nuclear periphery with the eventual formation of membrane-
bound apoptotic bodies that contain organelles, cytosol and nuclear fragments and are phagocytosed without 
triggering inflammatory processes. The necrotic cell swells, becomes leaky and finally ruptures and releases its 
contents into the surrounding tissue resulting in inflammation. [63]. 
 
The progress of apoptosis is regulated in an orderly way by a series of signal cascades. The 
caspase-cascade system plays a vital role in the induction, transduction and amplification of 
intracellular apoptotic signals [66]. The name caspases are derived from cysteiene-dependent 
aspartate –specific protease [63]. They are characterized by a cysteine containing active site 
with aspartate substrate specificity [67]. All caspases have a conservative pentapeptide active 
site QACXG (X cab be R, Q or D) [66, 63] and they specifically cleave their substrate after 
Asp residues [63]. Members of the caspase family differ significantly in their physiological 
roles, even though they have similarity in amino acid sequence and structures [60]. 
Caspases are synthesized as inactive proforms, but can become activated by proteolytic 
processing at conserved Asp residues [68, 69]. They contain an N-terminal pro-domain 
followed by the region that forms a two subunit catalytic effector domain [60]. The N-
terminal of the pro-domain in pro-caspases contains the highly diverse structure required for 
caspase activation. They are capable of auto activating as well as activating others [66]. Two 
main groups of caspases are categorized; initiator caspases (caspase -8, -9, -10, and -12), 
which cleave other caspases, or executioner caspases (caspase -3, -6, and -7) which cleave 
various cellular proteins [67]. 
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There are two major pathways through which the apoptotic caspase family protease can be 
activated [66]. 
 
1.6.1.1 Extrinsic pathway (death receptor- mediated pathway) 
The extrinsic pathways that initiate apoptosis involve transmembrane receptor-mediated 
interactions [58]. These receptors contain different death effector domains (DEDs) [33]. 
These death domains play a critical role in transmitting the apoptotic signals (after ligation 
with specific ligands) to the intracellular signalling pathways (Figure 1.6) [58, 67]. The best 
characterized ligands and corresponding death receptors include FasL/FasR, TNF-α/TNFR1, 
Apo3L/DR3, Apo 2L/DR4 and Apo 2L/DR5 [58]. Upon ligand binding, death receptors, such 
as CD95 (Apo-1/Fas), aggregate and form membrane-bound signalling complexes [70]. 
Binding of Fas ligand (FasL) to Fas receptors (FasR) result in the binding of adaptor protein 
Fas-associated death domain (FADD). Ligand binding to tumor necrosis factor (TNF) 
receptors result in the binding of the adaptor protein TNFR-associated death domain 
(TRADD) with recruitment of FADD and RIP [58, 70]. This results in the formation of death 
induced signal complex (DISC) which in turn leads to the auto catalytic activation of pro-
caspase-8 and triggering of the proteolytic caspase cascade [33, 58]. Activation of the 
initiator caspase-8 propagates the apoptosis signal by direct cleavage of downstream effector 
caspases such as caspase-3 and -7 [68, 71].  
Alternatively, active caspase -8 can activate the mitochondrion-mediated pathway by 
cleaving the Bcl2-homology domain 3 (BH3) of the protein BH3-interacting domain death 
agonist (BID) in the cytosol, into its active form trauncated BID (tBID). tBID will trigger the 
activation of the mitochondrion pathway [33, 66]. The release of cytochrome c, apoptosis- 
inducing factor (AIF) and other molecules from the mitochondria leads to the induction of 
apoptosis [66]. Death receptor-mediated apoptosis can be inhibited by a protein called cFLIP 
which will bind to FADD and pro-caspase-8, rendering them ineffective [33]. 
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Figure 1.6: Apoptosis signalling pathways. Apoptosis pathways can be initiated through different entry sites, for 
example, at the plasma membrane by death receptor ligation (receptor pathway) or at the mitochondria 
(mitochondrial pathway). Stimulation of death receptors of the tumor necrosis factor (TNF) receptor 
superfamily such as CD95 (APO-1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) receptors by CD95 
ligand (CD95-L) or TRAIL results in receptor aggregation and recruitment of the adaptor molecule Fas-
associated death domain (FADD) and caspase-8. Upon recruitment, caspase-8 becomes activated and initiates 
apoptosis by direct cleavage of downstream effector caspases [68]. 
 
1.6.1.2 Intrinsic pathway (mitochondrion-mediated pathway) 
Mitochondria are well known for their life sustaining production of ATP, but these organelles 
can also function as engines of cell death. This is due to the release of cytochrome c 
(activator of Apaf1/caspases), Smac [IAP (inhibitors of apoptosis protein) inhibitor] and AIF 
(endonuclease activator) [69]. Mitochondria are regarded as an important player mediating 
intrinsic death signals, and could serve as a novel target for chemotherapy [72]. The intrinsic 
pathway that initiates apoptosis involves a diverse array of non-receptor mediated stimuli. 
These stimuli produce intracellular signals that act directly on targets within the cell cycle 
and are mitochondrial initiated events (Figure 1.7) [58]. 
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Figure 1.7: Typical mitochondrion-mediated and caspase dependent apoptotic pathway [66]. 
 
This pathway is used extensively in response to diverse forms of cellular stress (e.g. DNA 
damage) [70]. These stressors promote the activation of pro-apoptotic proteins in the cytosol, 
which will induce the opening of mitochondrion permeability transition pores (MPTPs) [66, 
70]. The release of cytochrome c from the intermembrane space into the cytosol triggers 
caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing 
apoptosome complex [58, 68, 70]. Clustering of pro-caspase-9 leads to activation, whereas 
Smac/DIABLO [direct inhibitor of apoptosis protein (IAP) - binding protein with low PI] and 
Omi/HtrA2 are reported to promote apoptosis by inhibiting IAP [58, 68]. A second group of 
pro-apoptotic mitochondrial proteins (AIF, Endonuclease G) has been found to be released 
from the mitochondria that can cause apoptosis by DNA fragmentation and subsequent 
chromosomal condensation [58]. There is considerable cross-talk between the intrinsic and 
extrinsic pathway [33] with links at different levels [68]. 
 
1.6.2 Necrosis 
Necrosis (non-apoptotic, accidental cell death) is another mechanism of cell death [58]. It is 
considered a toxic process that is energy-independent [58]. This is the result of exposure to 
exogenous agents resulting in the loss of osmotic balance [62]. Rapid loss of cellular 
membrane potential distinguishes necrosis from apoptosis [73]. The influx of cations, which 
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poison respiration, results in the swelling of the endoplasmic reticulum and mitochondria. 
Ca
2+
 may activate Ca
2+
 dependent degradative enzymes to disrupt cellular membranes and 
randomly degrade DNA. The result is bursting of the cell and releasing of lysosomal and 
degradative enzymes that attack and severely injure or kill adjacent cells [62]. Morphological 
changes that occur with necrosis includes, cell swelling; formation of cytoplasmic blebs; 
swollen or ruptured mitochondria; disaggregation and detachment of ribosomes; disrupted 
organelle membranes; swollen and ruptured lysosomes and eventually disruption of cell 
membranes (Figure 1.5) [58]. 
 
1.7 Telomeres and telomerase 
Normal somatic cells divide for a limited number of times and eventually stop dividing 
through the process termed cellular senescence or replicative senescence [74- 76]. A major 
mechanism of cellular senescence involves shortening of telomeres. Telomeres are essential 
protein-DNA complexes forming capping structures at the end of eukaryotic chromosomes 
that protect chromosome ends from fusion and degradation [77-79]. Human telomeres 
contain long stretches of DNA tandem repeats TTAGGG [74, 80] which terminate in 3' 
protruding single stranded DNA overhang [80] primarily because the lagging strand of DNA 
synthesis is unable to replicate the extreme 3' end of the chromosome [74]. This is due to the 
fact that DNA-dependent DNA polymerase cannot completely replicate the ends of 
chromosomes so that more and more terminal DNA is lost with each cycle of DNA 
replication [79]. Critically short, dysfunctional telomeres eventually induce cells to senesce 
or die [75]. This end replication problem of the lagging strand and shortening of telomeres 
can be overcome by the expression of telomerase [81].  
Telomerase is a ribonucleoprotein enzyme [81-83] that uses its own RNA as template to add 
the hexanucleotide to the ends of replicating chromosomes [74, 83]. Its catalytic core consists 
of two major components, the RNA subunit (hTER) which provides the template and the 
catalytical subunit (hTERT). Other telomerase-associated proteins-hsp 90, p23, TEP1 and 
others may play a role in biogenesis and regulation [76, 82]. 
The absence or low telomerase activity in most human somatic cells prevents conventional 
DNA polymerase to replicate the ends of chromosomes resulting in replicative senescence 
[84]. In contrast to normal cells telomerase activity is detectable in the majority of cancer 
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tissue [74, 77]. Eighty to ninety percent of human tumours possess telomerase activity [85]. 
The nearly universal expression of hTERT in human cancers, its important role in promoting 
tumour proliferation and its restricted expression in normal tissue makes hTERT an attractive 
anti-tumour target [79, 85]. The gene for hTERT of telomerase was discovered in 1997 and 
soon thereafter targeted as well. The disruption of the telomeric structure and/or functions by 
drugs interacting with this substrate of the telomerase enzyme evolved into a promising way 
for telomerase inhibition [76]. 
 
1.8 Cancer therapies 
For many years surgery, radiation therapy, chemotherapy and hormone therapy have been the 
mainstays of cancer treatment [86]. Cancer therapy, for example, chemotherapy, ᵞ-irradiation, 
immunotherapy or suicide gene therapy, primarily exert their anti-tumour effect by triggering 
apoptosis in cancer cells [68]. Chemotherapy has been a mainstay anticancer treatment for 
many decades [87]. However chemotherapy is highly inadequate due to the lack of cytotoxic 
drug specificity [87, 88] and the consequent generation of toxic side effects when high doses 
are administered [87]. During anticancer treatment it is difficult to protect the healthy cells 
from side effects by the drugs administered [89].       
The ideal situation would be that chemotherapeutic drugs should specifically target only 
cancerous cells by inducing a cytotoxic and/or cytostatic effect with minimal damage to 
normal cells. Systemic toxicity due to lack of specificity, rapid metabolism and both intrinsic 
and acquired drug resistance has decreased the effectiveness of chemotherapy [71]. Despite 
many therapeutic advances in the understanding of the process in carcinogenesis, overall 
mortality statistics are unlikely to change until there is a reorientation of the concepts for the 
use of natural products as chemo preventive agents. Natural or semi synthetic compounds 
may be used to block, reverse, or prevent the development of invasive cancers [3]. 
 
 
 
 
21 | P a g e  
 
1.9 Cancer incidence in developing countries and use of medicinal plants 
as alternative and complementary therapeutic agents 
The global increase in cancer especially in developing countries is a serious concern as 
documented in reports of the World Health Organization (WHO) [90]. It was estimated by 
the WHO that cancer will be the leading cause of death in the world by 2010 [91]. In 2008, 
approximately 72% of cancer deaths occurred in low and middle income countries [91, 92]. A 
challenge facing the developing countries in cancer control is poverty [91] and priority for 
cancer care is rated low [90]. The high cost of treatment and lack of healthcare insurance 
system for the poor is a fundamental problem in cancer control in developing countries [92]. 
According to the WHO, 80% of the world’s population, primarily those of developing 
countries, rely on plant derived medicine for their health-care [93, 94]. Traditional African 
Medicine (TAM) serves as major African Socio-cultural heritage servicing over 80% of the 
population in Africa, in existence for several hundred of years, was once believed to be 
primitive and wrongly challenged with animosity [95]. The fact that the people do not have 
scientific insight to explain and predict the curative action of plants is one of the reasons why 
medicinal plants are often associated with witchcraft and superstition. The people may not 
understand the scientific rationale behind their medicines, but they know from personal 
experience that some medicinal plants can be highly effective if used at therapeutic doses 
[93]. Thus, the major challenge for the usage of medicinal plants is scientifically based 
evidence, quality standards and regulations that needs to be developed at the same pace as the 
demands for the medicine [95].  
Plant drugs fell into disfavour with the rise of the modern pharmaceutical industry in the 
early 20
th
 century [96]. Since a large majority of the developing countries of the world were 
unable to provide healthcare to the populations using the imported orthodox health facilities, 
the WHO are supporting, promoting and assisting the development of traditional medicine to 
help move the African health agenda forward [95]. For the maintenance of good health in 
developing countries, traditional medicine and medicinal plants are used [97]. 
Plants have a long history of use in the treatment of cancer, it has played an important role as 
source of effective anticancer agents and it is significant that over 60% of currently used 
anticancer agents are derived in one or another form from natural sources [98]. The search for 
anticancer agents from plant sources started in the 1950’s with the discovery and 
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development of the vinca-alkaloids, vinblastine and vincristine from Vinca rosa L 
(Periwinkle) [98, 99]. Epiphodophyllotoxin analogs (VP-16 and VM-26) are other drugs 
derived from medicinal plants [99].  
Most of the current drugs are synthesized against the backbone of one or another natural 
product [3]. Anticancer drugs, such as paclitaxel was originally isolated from the taxol extract 
of the bark of the Pacific yew, Taxus brevifolia. Paclitaxel is used to treat drug-refractory 
ovarian cancer and metastatic breasts cancer, small and non- small lung cancer [99]. 
Paclitaxel acts by inhibiting microtubule depolymerisation and promotes tubulin assembly 
and inhibits all proliferation [3, 100]. Paclitaxel’s structure was elucidated in 1971 and was 
clinically introduced to the US market in the early 1990s.  
Numerous types of bioactive compounds have been isolated from plant sources [94]. Africa is 
a rich source of medicinal plants where researchers can use ethnomedical data to increase 
their chance of finding plants with anticancer activities [97]. 
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Chapter 2: Aim and objectives of study 
Cancer is one of the most prominent human diseases which have stimulated scientific and 
commercial interest in the discovery of new anticancer agents from natural sources. In Africa 
the majority of people use plant based traditional medicine, where traditional healers have 
been treating various cancers and cancer-related conditions for ages [101]. 
Due to its large geographical spread, Africa is one of the continents with the richest 
biodiversity in the world, however little effort has been devoted to the development of 
chemotherapeutic agents from these plants.  Therefore, detailed evaluation of the constituents 
and screening of bioactive substances for chemotherapeutic purposes of African plants are 
urgently warranted. Furthermore, this will serve to validate the efficacy and safety of African 
traditional medicine.   
This study aims to investigate the in vitro anticancer activity of previously identified Nigerian 
medicinal plants with the intension of providing scientific evidence for the use of African 
traditional medicine as economical alternative for community healthcare. The plants that 
were investigated are listed as follows: Sapium ellipticum leaves, Sapium ellipticum  
stembark, Combretum paniculatum, Celosia trigyna, Pupalia lappacea, Justica extensa, 
Hedranthera barteri leaves, Alternanthera sessilis, Ethulia conyzoides leaves, Lannea 
nigritana stembark, Combretum zenkeri root, Combretum molle leaves, Adenanthera 
parvoniana, Lannea acida, Cyathula achyranthoides, Drymaria cordata, Cyathula prostrata, 
Uvaria chamae and  Lecaniodiscus cupanioides (Table 2.1). The extracts were screened for 
cytotoxicity against human cancer cell lines as well as Chang liver cells and peripheral blood 
mononuclear cells (PBMCs). The extracts were further screened for effects on levels of the 
catalytic subunit of the telomerase enzyme, hTERT. Based on the screening results, a few 
extracts were selected for fractionation and active compound isolation and the mechanism of 
cell death was investigated. The fractions and isolated compounds that were investigated 
further are listed in Table 2.2.  Some of the active extracts were identified for further studies 
by other students in the research group.  These will be pointed out in later chapters. 
Plant selection was based on their frequency in recipes for the management of cancer from an 
ethnobotanical survey of traditional medical practitioners in South-Western Nigeria. This 
survey was performed by Dr AA Sowemimo, a research collaborator from the University of 
Lagos. As part of our ongoing and growing collaboration with Dr Sowemimo, we were first 
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supplied with 17 extracts prepared from 16 Nigerian plants. After screening of these 17 
extracts was complete, she prepared and supplied three more extracts of the plants U. chamae 
and L. cupanioides to be investigated for in vitro anticancer activity.  Results for the first 17 
extracts are reported in Sections 4.1, 4.2 and 4.3.  Cytotoxicity screening of the additional 
two plants is reported in Section 4.4. 
Table 2.1: List of plants screened for anticancer activity 
Extract 
number 
Name of Plant Part used Medicinal Uses Ref. 
1a Sapium ellipticum (Krauss.) Pax. 
(Euphorbiaceae) 
Leaves 
Wounds, sore eyes and 
abdominal swelling  
102 
1b Sapium ellipticum (Krauss.) Pax. 
(Euphorbiaceae) 
Stembark 
 
Purgative, eczema, scurvy 
and stomatitis 
102 
2 Combretum paniculatum Vent. 
(Combretaceae) 
Leaves Flower: -inflammation, 
root:tumours 
103 
3 Celosia trigyna L. (Amaranthaceae) Whole plant Malaria, fever, intestinal 
worms, headache, nose 
inflammation, pain during 
pregnancy, uterus pain. 
104 
4 Pupalia lappacea (L.) A. Juss 
(Amaranthaceae) 
Whole plant Treatment of boils, chronic 
and fresh wounds, piles, 
enema for fever and 
malaria. 
105, 
106 
5 Justica extensa T. Anders 
(Acanthaceae) 
Whole plant Leaf: arthritis, rheumatism, 
pain; small-pox, chicken-
pox, measles,  
Leaf, flower: diarrhoea, 
dysentery 
Leaf, root: paralysis, 
epilepsy, convulsions, 
spasm; pulmonary troubles; 
skin, mucosae 
Leaf-sap: cutaneous, 
subcutaneous parasitic 
infection 
Plant: fish-poisons 
Root: febrifuges 
 
 
 
107 
6 Hedranthera barteri (Hook.f.) 
Pichon (Apocynaceae) 
Leaves Treatment of painful 
tumour, dizziness, pain 
inflammation. 
108, 
109 
7 Alternanthera sessilis L. DC.  Whole plant Treatment of infected 
wounds, sprains, burns, 
eczema, carbuncle, acute 
conjunctivitis, snakebites, 
dysentery, diarrhoea, acne 
and pimples. 
110 
8 Ethulia conyzoides Linn. F. 
(Asteraceae) 
Leaves Anthelminthic for round 
worms and abdominal 
disorders. 
111 
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Table 2.1 continued... 
Table 2.1: List of plants screened for anticancer activity 
Extract 
number 
Name of plant Plant part 
used 
Medicinal Uses Ref. 
9 Lannea nigritana (Scott Elliot) Keay 
SB. (Anacardiaceae) 
 
 
Stembark Bark: diarrhoea, 
dysentery, pain. Bark 
root: pulmonary 
troubles, skin, 
mucosae. Bark-sap: 
paralysis, epilepsy, 
convulsion, spasm. 
Seed: laxatives. Twig: 
stomach troubles. 
 
 
 
 
112 
10 Combretum zenkeri Engl.& Diels 
(Combretaceae) 
Root Purgative and 
vermifuge, malaria, 
menstrual pain, worm 
treatment and oedemas. 
113 
 
11 Combretun molle R.BR 
(Combretaceae) 
Leaves Leaves: chest 
complaints 
anthelmintic, inhalant, 
snake bite. Root: 
induce abortion, treat 
constipation, leprosy, 
headaches, stomach 
pains, fever, dysentery, 
general pains. 
114 
12 Adenanthera parvoniana L. 
(Mimosaceae) 
Fruits Bark, leaves, seeds: 
arthritis, gout, burning 
sensation, vomiting, 
fever, haemorrhoids, 
and diarrhoea. 
115 
13 Lannea acida A. Rich 
(Anacardiaceae) 
Stembark Eye treatments, anal 
haemorrhoids, 
diarrhoea, dysentery, 
oral treatments, 
stomach pains, 
rheumatism, and 
gonorrhoea. 
116,117 
14 Cyathula achyranthoides (Kunth.) 
Moq. (Amaranthaceae) 
Whole plant Flowers and leaves: 
applied to dog bites, 
relieve headaches, 
fever. 
118 
15 Drymaria cordata (Linn.) Willd. 
(Caryophyllaceae) 
Whole plant Antidote, appetizer, 
depurative, emollient, 
febrifuge, laxative and 
stimulant, sinus, boils. 
119,120 
16 Cyathula prostrata (Linn.) Blume 
(Amaranthaceae) 
Whole plant Root: fever, oitment for 
scrotum to enable 
dilatation 
121,122 
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Table 2.1 continued. 
Table 2.1: List of plants for anticancer activity 
Extract 
number 
Name of plant Plant part 
used 
Medicinal Uses Ref. 
U Uvaria chamae P. Beauv 
(Annonaceae) 
 Root bark: respiratory 
catarrh, piles, 
menorrhagia, epistaxis, 
haematuria and 
Haemolysis, 
abdominal pains. 
 
123 
LL 
LR 
Lecaniodiscus cupanioides Planch 
ex Benth (Sapindaceae) 
Leaves 
Root 
Treatment of wounds 
and sores, abdominal 
swelling caused 
by liver abscess, fevers, 
measles, hepatomegaly 
and burns 
124 
 
Table 2.2: List of selected plant fractions and isolated compounds screened for anticancer 
activity. 
Plant crude extract Fractions Isolated Compounds 
Sapium ellipticum  (Leaves)  SPE- Petroleum ether  
 
 
SB - Butanolic 
SAQ – Aqueous  
 
SEA – Ethyl acetate  
 
SV 2-2a                                                                                                                                                                 
SV 2-2b 
SV2-3-3 
Scf - Chloroform 
SCL V2-2 
SCL V2-3 
Combretum paniculatum (Leaves)                                                            Cpl - Aqueous  
Cpl - Petroleum ether 
Cpl - Ethyl acetate 
Cpe 4-4 
Cpe 3-4 
Cpe 4-9 
Lecaniodiscus cupanioides  
(Leaves) 
LL(Aq) - Aqueous 
 
LL(B) - Butanolic 
LL(Etb) - Ethyl acetate A 
LL(Eta) - Ethyl acetate B 
LL(H) - Hexane 
LL(Cl) - Chloroform 
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Chapter 3: Materials and methods 
3.1  Plant material and extraction 
All tested plants were collected from the Olokemeji Forest Reserve and from the Campus 
Obafemi Awolowo University, Ile-Ife, Nigeria in July 2006. They were authenticated by 
comparison with corresponding herbarium specimens by Mr Daramola at the Forestry 
Research Institute, Ibadan, Nigeria (FRIN) where voucher specimens were also deposited. 
The plants were dried in a hot air oven at 40
0
C, ground to powder and stored in amber 
coloured bottles. One hundred grams of each powdered plant material was macerated with 
80% ethanol at room temperature. The resulting extracts were filtered and concentrated to 
dryness in vacuo at room temperature. The respective plant parts used are as stated in Table 
2.1. 
Fractions of selected extracts were prepared at the University of Lagos and compounds 
isolated at the Peking University, Beijing, China. The method was described in a journal 
article recently accepted for publication (Addendum 2). 
3.1.1  Plant extract preparation for screening 
Plant extract stock solutions (100 mg/ml) were prepared fresh on the day of the experiment. 
The extracts were dissolved in dimethyl sulfoxide (DMSO) (Saarchem Unilabs) at 100 mg/ml 
to make a stock solution. The test concentrations were obtained by diluting the stock solution 
with RPMI 1640 containing 25 mM Hepes and 2 mM glutamine (Lonza), supplemented with 
10% foetal bovine serum (FBS) (Gibco). The final concentration of DMSO to which cell 
cultures were exposed never exceeded 0.25% and a vehicle control was included in all 
experiments. 
3.2  Growth and maintenance of cell lines 
Cancer cell lines HT29 (colon cancer), HeLa (cervical cancer), MCF-7 (breast cancer) and 
U937 (histiocytic lymphoma) and a non-cancerous cell line (Chang Liver) was taken from 
liquid nitrogen stocks. The cells were thawed in a water-bath (37°C) and transferred to 10 cm 
culture dishes (Nunc) for adherent cell lines and a 50 ml suspension
 
flask (Nunc) for U937 
suspension cultures. The 1 ml thawed cell stock was diluted with 9 ml pre-warmed RPMI 
1640 medium containing 25 mM Hepes and 2 mM L-glutamine (Lonza) supplemented with 
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10% FBS (Gibco). The cells were incubated for approximately 4 h in a 37°C humidified 
incubator with 5% CO2 to allow them to attach. The growth medium was removed and fresh 
growth medium was added to remove DMSO present in the freeze medium. The suspension 
cell culture (U937) was centrifuged at 300 x g for 5 minutes, the pellet resuspended in 10 ml 
pre-warmed growth medium and transferred to a 50 ml flask and incubated in a 37°C 
humidified incubator with 5% CO2. Cells were viewed using an inverted phase contrast 
microscope to assess the degree of confluency and to confirm the absence of bacterial and 
fungal contaminants. When a confluence of ~80% was reached, cells were sub-cultured. 
U937 cells were maintained at a density between 1x10
5
 and 1x10
6 
cells/ml [125]. 
3.2.1 Sub-culture of cells 
When cells reached 80% confluency they were sub-cultured. The growth medium was 
aspirated and the cells were washed twice with 5 ml phosphate buffered saline containing no 
Mg
2+
 or Ca
2+
 (PBSA). One milliliter 0.25% (w/v) trypsin (Roche) was added to the plate to 
detach cells from the surface. Within a few seconds of allowing the trypsin to cover the 
surface of the plate, it was aspirated. The dish was incubated at 37°C for 10 min. The cells 
were resuspended in 1 ml growth medium. To determine the amount of viable cells, 20 µl of 
the cell suspension was transferred to an eppendorf tube containing 20 µl of trypan blue 
[0.4% (w/v) in PBS]. The cell suspension was counted on a Neubauer haemocytometer. The 
cell suspension was replated into new culture dishes at a ratio of 1:5 and incubated [125]. 
 
3.3 Determination of cytotoxic activity 
3.3.1  Screening of extracts, fractions and compounds using the MTT assay 
Traditionally the determination of cell growth is done by counting the viable cells after 
staining with a vital dye. The yellow MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide, a tetrazole) is reduced to a purple formazan product in the 
mitochondria of living cells. The absorbance of this coloured compound can be quantified 
after solubilisation in DMSO and by measuring the absorbance at a certain wavelength 
(usually between 500 and 600 nm) by a spectrophotometer. This reduction takes place only 
when mitochondrial reductase enzymes are active, and therefore conversion can be directly 
related to the number of viable (living) cells [126].  
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Cells in an exponential growth phase were trypsinized, counted using a Neubauer 
haemocytometer and diluted to a density of 30 000 cells/ml. The cells were seeded into a 96-
well plate at 6 000 cells/well in 200 µl aliquots in RPMI 1640:10% FBS. Plates were 
incubated at 37°C for 24 hours to allow cells to attach. The plant extracts, fractions and 
isolated compounds were screened for cytotoxicity using concentrations ranging from 1–250 
µg/ml. Cisplatin served as a positive control in concentrations ranging from 10 – 100 µM. 
Following the initial 24 hour incubation period, the growth medium was removed and 200 µl 
aliquots of the plant extracts, isolated compounds or cisplatin were added and the plates 
incubated for a further 48 hours. After the 48 hour incubation period the medium was 
replaced with 200 µl MTT (Sigma) (0.5 mg/ml in RPMI 1640: 10% FBS). The MTT was 
removed after a further 4 hour incubation at 37°C and the purple formazan product dissolved 
in 100 µl/well DMSO. Plates were agitated for 60 seconds and absorbance measured at 540 
nm on a multiwall scanning spectrophotometer (Multiskan MS, Labsystem). All incubation 
steps were carried out in a 37°C humidified incubator with 5% CO2. 
3.3.2 Screening of extracts, fractions and compounds on peripheral blood 
mononuclear cells (PBMCs) 
This is an important control mechanism to test the cytotoxic effects of the plant extracts on 
normal healthy cells. 
3.3.2.1 PBMC isolation, seeding and treatment 
Raw blood was collected from a healthy donor using heparinised Vacutainer® CPT™ cell 
preparation tubes (Becton Dickinson). Within 30 minutes of collection, blood was 
centrifuged at 1 800 x g for 30 minutes at 20°C. The tube was inverted and the top layer 
containing plasma together with the PBMCs was transferred to a sterile 15 ml falcon tube. 
Centrifugation followed at 300 x g for 15 minutes, followed by aspiration of the plasma. The 
pellet was resuspended by grating the tube over a round-bottom plate. Ten milliliters RPMI 
1640:10% FBS was added and centrifuged at 300 x g for 15 minutes and the supernatant 
discarded. This wash step was repeated twice. The pellet was resuspended and diluted to the 
desired cell density. PBMCs were seeded at 100 000 cells/ml in 100 µl aliquots in round 
bottomed 96-well plates. One hundred microliters of cisplatin concentrations ranging from 1 - 
100 µM and 100 µl of selected plant extracts with concentrations ranging from 8 – 250 µg/ml 
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were added to the PBMCs and incubated for 48 hours at 37°C. Viability was determined 
using the Cell Titre Blue assay as described in the next section. 
3.3.2.2 Cell Titre Blue assay 
Cell Titre Blue Viability assay uses the dark blue indicator dye resazurin to measure the 
metabolic capacity of cells – an indicator of cell viability. Viable cells retain the ability to 
reduce resazurin into resorufin (pink), which is highly fluorescent. Non-viable cells rapidly 
lose metabolic capacity, and do not reduce the indicator dye and thus do not generate a 
fluorescent signal. 
Following the 48 hour incubation period, 40 µl of the Cell Titre Blue reagent was added to 
the plates. Plates were covered with tin foil and incubated for a further 4 hours at 37°C. 
Flourescence was read at an excitation wavelength of 560 and an emission wavelength of 590 
nm using a Fluoroskan Ascent FL Fluorometer (Thermo Labsystem, Finland). The IC50 of the 
cisplatin and the selected plant extracts was determined using GraphPad Prism 4 program 
[127]. 
 
3.3.3 Dose response curves     
Dose response curves for cisplatin and any of the plant extracts that gave more than 50% 
growth inhibition over the tested concentration range, were prepared. This was done in order 
to obtain the IC50 values of the cisplatin and the selected plant extracts, using the log-dose 
response curve in the GraphPad Prism 4 program. One of the extracts with the lowest IC50 
value was selected for further investigations and in those assays, the cells were treated with 
an extract concentration equal to the IC50 value. 
 
3.4 hTERT immunodetection 
Increasing data suggest that hTERT can serve as target for widely applicable immunotherapy 
against cancer. The critical role of telomerase in tumour growth and development suggests 
that hTERT down regulation may have a deleterious effect on tumour growth [128].  
For detection and quantification of hTERT levels in treated and control cells, cells were fixed 
and permeabilised using the IntraPrep
TM
 kit (Beckman Coulter) before immunodetection 
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using flow cytometry. A primary anti-hTERT antibody and a FITC-conjugated secondary 
antibody were used to detect the target protein. 
3.4.1 hTERT screening  
U937 cells were seeded at 100 000 cells/well in 500 µl aliquots in a 24 well plate. An equal 
volume of cisplatin or selected plant extract was added to the plates giving a final cisplatin 
concentration of 50 µM or extract concentration of 12.5 and 125 µg/ml. After the treatment 
exposure period of 48 hours cells were transferred to polypropylene flow cytometry tubes 
(Beckman Coulter), centrifuged at 300 x g for 5 minutes and the supernatant discarded and 
the pellet washed twice with PBS. Fifty microliters IntraPrep
TM
 1 reagent was added, 
vortexed and incubated for 15 minutes at room temperature. The cells were washed with 1 ml 
PBS, centrifuged at 300 x g for 5 minutes and the supernatant discarded. Fifty microliters of 
IntraPrep
TM
 2 reagent was added and incubated for 5 minutes at room temperature. Cells 
were washed in 1 ml PBS supplemented with 0.5 % bovine serum albumin Fraction V (BSA) 
(Roche) and centrifuged at 300 x g for 5 minutes at room temperature and the supernatant 
discarded. Cells were resuspended in 100 µl PBS-BSA and allowed to incubate for 10 
minutes at room temperature. Two microliters of primary antibody (primary rabbit anti-
human hTERT antibody from Santa Cruz Biotechnology, Inc.) was added to the positive 
control, negative control and treated cells but not to the isotype control and incubated for 60 
minutes at room temperature. Cells were washed with 1 ml PBS-BSA and centrifuged at 300 
x g for 5 minutes and the supernatant discarded, leaving approximately 100 µl in the tube. 
Two microliters of the secondary antibody [Goat Anti-Rabbit IgG fluorescein isothiocyanate 
(FITC)-conjugate from Santa Cruz] was added to all the tubes except the isotype control 
which received 5 µl of the isotype antibody (Rabbit IgG-FITC from Beckman Coulter) and 
incubated for 30 minutes at room temperature. Cells were washed in 1 ml PBS-BSA, 
centrifuged at 300 x g for 5 minutes and the supernatant discarded. Three hundred microliters 
PBS-BSA was added to the tubes and the samples analyzed by flow cytometry using a 
Beckman Coulter® FC 500 Flow Cytometer (Miami FL, USA).                                                                                                                                                                                                                                                               
 
3.4.2 GAPDH and β-Actin reference proteins  
To better explain biological end experimental variations it is best to include specifically 
selected internal reference control(s) for data normalization. The expression of the reference 
control(s) should be constant across all samples and different phases of the cell cycle [129]. 
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were selected as reference 
proteins to verify any variations of hTERT levels in the different cell lines under the various 
plant treatments. 
The measurement of GAPDH and β-actin followed the same method that was used for 
hTERT screening except for the use of different primary antibody GAPDH (14C10) Rabbit 
mAb and β-actin (13E5) Rabbit mAb (Cell Signalling), respectively. 
 
3.5 Cell cycle analysis 
The sequence of cell cycle events can be identified as follows: Initiating from a quiescent or 
resting phase (phase G0), cell growth and preparation of chromosomes for replication takes 
place in phase G1. The cell continues with synthesis of DNA (S phase) and is followed by 
preparation for cell division (phase G2). Finally mitosis (M phase) occurs and is perpetuated 
with newly divided cells. Flow cytometry offers a rapid method for measuring the DNA 
content of cells and provides a convenient research tool to monitor cell cycle status and 
regulation. An exponentially growing population of cells will have a DNA content 
distribution containing an initial peak of G0/G1 cells, a valley of S phase, and a second peak 
containing G2/M cells. Measurement can be performed and is based on the ability of nuclear 
dyes, such as DAPI and PI, to bind selectively and at a characteristic stoichiometric ratio to 
DNA under appropriate staining conditions. The DNA Prep Kit from Beckman Coulter was 
used as per manufacturer’s recommendations [130].  
Hela, HT29 and MCF-7 cancer cells were seeded in 10 cm culture dishes at 1.2 x 10
6
 
cells/dish, in 10 ml complete medium and left to attach for 24 hours at 37°C in a humidified 
incubator and 5% CO2. After attachment, medium was aspirated and the treatment added. 
Enough culture dishes were prepared for 6, 16, 24 and 48 hours of treatment. At these 
incubation times, the medium was transferred to polypropylene flow cytometry tubes, the 
tubes centrifuged at 300 x g for 5 minutes and the supernatant discarded. This was done to 
collect cells that may have detached during incubation. The adherent cells were washed twice 
with phosphate buffered saline (Ca
2+ 
and Mg
2+
 free) (PBSA), trypsinized for 10 minutes and 
resuspended in 1 ml sheath fluid (Beckman Coulter) and transferred to the polypropylene 
flow cytometry tubes already containing the detached cells. The cells were centrifuged at 300 
x g for 5 minutes, the supernatant discarded and the pellet was gently vortexed. The Coulter
®
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DNA Prep™ reagent kit (Beckman coulter) was used for DNA cell cycle analysis. One 
hundred microliters Lysis buffer (0.1% NaN3, non-ionic detergents, saline and stabilizers) 
was added to each tube and incubated for 5 minutes at room temperature. Five hundred 
microliters of propidium iodide (PI) was added and incubated in the dark for 15 minutes at 
37°C. Samples were analyzed using a Beckman Coulter Cytomics FC500 (Miami FL, USA). 
3.6 Apoptosis detection: Annexin V-FITC/PI staining 
In most viable eukaryotic cells, the negatively charged phosphatidylserine (PS) is located in 
the cytosolic leaflet of the plasma membrane lipid bilayer. PS translocation from the inner to 
outer leaflet is an early event during apoptosis [131]. Annexin V is a PS-binding protein that 
interacts strongly and specifically with PS residues and can be used for the detection of 
apoptosis [58] via flow cytometry when fluorescently conjugated [60]. Apoptotic cells can be 
directly detected through their staining with fluorochrome-conjugated Annexin V. Dual 
staining with Annexin V and PI enables one to differentiate between necrotic and apoptotic 
cell death. PI is able to penetrate necrotic cells through their compromised plasma 
membranes and these cells will therefore stain positive for PI.  Dead cells (in the later stages 
of apoptosis or necrosis) are stained with both Annexin V and PI, whereas viable cells cannot 
be stained with either. 
U937 cells were seeded at 100 000 cells/ml in a 24-well plate treated with DMSO (0.25%, 
v/v), ciplatin (5 and 50 µM) or S. ellipticum leaf extract (125 µg/ml) and incubated for 24 
hours at 37°C in a humidified incubator and 5% CO2. Following the incubation period cells 
were transferred to polypropylene flow cytometry tubes and centrifuged at 500 x g for 5 
minutes at room temperature. Cells were washed in ice-cold Dulbecco’s Modified Eagle’s 
Medium (DMEM) and centrifuged at 500 x g for 5 minutes at 4°C. The protocol of the 
Annexin V-FITC/PI Apoptosis Detection kit (Beckman Coulter) was used. The supernatant 
was discarded and the pellet resuspended in ice-cold 1X binding buffer. Annexin V-FITC (1 
µl) and PI (5 µl) were added to each tube. Tubes were gently mixed and incubated on ice for 
15 minutes in the dark. Control tubes for setting up the flow cytometry protocol contained, 
cells with Annexin V-FITC only, PI only and combination of Annexin V-FITC and PI. 
Samples were read on a Beckman Coulter Cytomics FC500 (Miami FL, USA).  
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3.7 Data analysis 
For cytotoxicity screening results with fractions and isolated compounds, quadruplicate 
results of treated cells were compared to vehicle control cells using the two-tailed Student’s t-
test assuming equal variances. For flow cytometry experiments, a minimum of 10 000 cells 
were analysed per sample. For cell cycle analysis and Annexin V-FITC/PI assays, duplicate 
samples were prepared and analysed. For screening of hTERT levels, only single samples 
were run. 
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Chapter 4: Results 
4.1 Cytotoxic screening using MTT assay and Cell Titre Blue assay  
The MTT assay was used to determine cell viability for adherent cells (HT29, MCF-7, HeLa 
and Chang liver cells) and the Cell Titre Blue assay for PBMCs that are cultured in 
suspension. 
4.1.1 Cytotoxic screening of 17 medicinal plant extracts against HeLa cells 
The potential cytotoxicity of 17 medicinal plants was evaluated in a pre-screen against HeLa 
cervical cancer cells using the MTT viability assay. The crude extracts were initially pre-
screened against HeLa cells using two concentrations (250 and 500 µg/ml). From the results 
of this pre-screen, extracts were selected for further screening against HT29 and MCF-7 cells. 
The MTT cytotoxicity results are as shown in Figure 4.1 with extract numbers corresponding 
to those in Table 2.1. Cisplatin at 10 and 100 μM caused 49.25 ± 3.33% and 88.19 ± 0.60% 
(SEM, n=4) inhibition, respectively. In consideration of the cytotoxicity, the extracts could be 
 
Figure 4.1: Screening results of seventeen extracts, prepared from sixteen plants, on HeLa cervical cancer cells.  
Results represent the mean ± standard error of the mean of quadruplicate determinations.  Cisplatin as positive 
control at 10 and 100 μM caused 49.25 ± 3.33% and 88.19 ± 0.60% (SEM, n=4) inhibition, respectively (not 
shown on graph). 
 
classified into four categories according to their relative toxicities. Firstly, potentially 
cytotoxic were S. ellipticum leaves, C. paniculatum leaves, C. trigyna, D. cordata and C. 
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prostrata showing over 50% activity at 500 µg//ml. Secondly, moderately cytotoxic were E. 
conyzoides leaves, H. barteri leaves and C. achyranthoides showing between 40-50% activity 
at 500 µg/ml. Thirdly, low cytotoxic were P. lappacea, J. extensa, S. ellipticum stembark, A. 
sessilis, L. nigritana stembark and C. zenkeri root showing less than 40% activity at 500 
µg/ml. Lastly, non-toxic were C. molle, A. parvoniana fruit and L. acida stem bark with no 
activity against the HeLa cell line. 
 
4.1.2 Further screening of five selected plant extracts against HT29 
and MCF-7 cell lines 
S. ellipticum leaves, C. paniculatum leaves, C. trigyna, D. cordata and C. prostrata showing 
over 50% activity at 500 µg/ml  against HeLa cancer cells were selected for further screening 
against HT29 and MCF-7 cancer cell lines at 250 and 500 µg/ml. The plant names, parts used 
and new extract numbers allocated for further screening are summarised in Table 4.1. 
Table 4.1 List of five selected plants used in the cytotoxicity assay against HT29 and MCF-7 
cells 
a 
FRIN No.: Herbarium number of collections lodged at the Forestry Research Institute (FRIN) at Ibadan, 
Nigeria 
Figure 4.2 shows the cytotoxicity results with extract numbers corresponding to those in 
Table 4.1. Cisplatin caused 48.5 ± 2.41, 78.0 ± 0.61 and 72.0 ± 1.47, 82.0 ±1.31 % inhibition 
(SD, n=4) at 10 and 100 μM inhibition for MCF-7 and HT29 cancer cells, respectively. In the 
MCF-7 breast cancer cell line, S. ellipticum had comparable activity to the positive control 
Extract number Plant name (Family) [FRIN No.
a
] Plant part used 
 
P1 
 
Sapium ellipticum (Krauss.) Pax. (Euphorbiaceae) [108265] 
 
Leaves 
P2 
 
Combretum paniculatum Vent. (Combretaceae) [107980] Leaves 
P3 
 
Celosia trigyna L. (Amaranthaceae) [84438] Whole plant 
P4 
 
Drymaria cordata (Linn.) Willd. (Caryophyllaceae) [107678] Whole plant 
P5 
 
Cyathula prostrata (Linn.) Blume (Amaranthaceae) [107232] Whole plant 
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cisplatin for all the concentrations tested. C. prostrata showed 50% inhibition at 500 µg/ml 
while C. paniculatum, C. trigyna and D. cordata showed inhibition lower than 50% for all 
the concentrations tested. However, in the HT29 colorectal cancer cell line none of the tested 
plants extracts showed inhibition comparable to the control drug cisplatin. All the plant 
extracts showed inhibition less than 50% in this cell line. Of all the extracts tested, Sapium 
leaves showed the highest activity and this was also observed in the HeLa cancer cell line.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Results of cytotoxic activity of extracts P1-P5 on HT29 and MCF-7 cancer cells. Results represent 
the mean ± SD of quadruplicate determinations. Cisplatin was used as positive control. P1- Sapium ellipticum, 
P2- Combretum paniculatum; P3- Celosia trigyna; P4- Drymaria cordata; P5- Cyathula prostrata. 
 
Three extracts were selected for further investigation based on the screening results reported 
here: S. ellipticum and C. paniculatum were included in the present study and results are 
reported in sections 4.1.3, 4.1.4 and 4.3. C. prostrata leaf extract was the topic of another 
MSc study done by Mr Gerald Schnablegger. 
4.1.3 Cytotoxic evaluation of S. ellipticum leaf crude extract, 
fractions and compounds 
S. ellipticum (Hochst) Pax (Euphorbiaceae) is a tree reaching to about 15 m high. It is widely 
distributed from Senegal to West Cameroon and across tropical Africa into KwaZulu-Natal in 
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South Africa [102]. The leaf preparation is used for sore-eyes and abdominal swelling while 
in Tanzania a preparation of dried leaves is applied to wounds [102].  
S. ellipticum (leaf) crude extract is being used in Nigeria as an anti-cancer treatment. The pre-
screening of the plant extract against HeLa, HT29 and MCF-7 cancer cells has shown its  
high cytotoxic activity against HeLa and MCF-7 cancer cell lines with less cytotoxicity 
against HT29 cancer cell line. Therefore, the crude ethanolic extract, five different fractions 
prepared from the ethanolic extract and five isolated compounds (Table 2.2) were subjected 
to further anti-cancer screening.  
4.1.3.1 S. ellipticum crude extract: IC50 determination  
4.1.3.1.1 HeLa, HT29 and MCF-7 cancer cell lines 
In order to determine IC50 values for the crude ethanolic extract of S. ellipticum leaves, it was 
tested against HeLa and MCF-7 cancer cell lines at concentrations ranging from 4 – 500 
µg/ml and HT29 at concentrations ranging from 2 – 250 µg/ml. Cisplatin as positive control 
was tested at concentrations ranging from 1.5 – 100 µM against HeLa cells and at 10 and 100 
µM against the other two cell lines.  
The results from the MTT assay are shown in Figure 4.3 (A-C). All the treatments showed 
dose-dependent cytotoxic effects. The results further confirm the observation from the 
previous section where HT29 cells were the least susceptible to the extract (Figure 4.2 and 
4.3 B). In contrast, the three cell lines all seemed to respond with similar sensitivity to 
cisplatin.  
Using GraphPad Prism software, IC50 values were calculated for all the dose-response curves 
where the maximum percentage inhibition was higher than 50%. The IC50 for cisplatin 
against HeLa cells was 7.60 ± 0.39 µM. For the crude extract against HeLa and MCF-7 cells, 
the IC50 values were 88.60 ± 0.03 and 93.09 ± 0.03 µg/ml, respectively (Figure 4.4). An IC50 
could not be calculated for HT29 cells due to the low percentage inhibition observed. 
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Figure 4.3: Cytotoxicity results of S. ellipticum leaf extract against (A) HeLa, (B) HT29 and (C) MCF-7 cancer 
cells. The positive control, cisplatin was screened at a concentration range of 1.5 – 100 µM against HeLa cancer 
cells. Results represent the mean ± SD of quadruplicate determinations. 
A 
B 
C 
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4.1.3.1.2 PBMCs and normal human Chang liver cell line 
Current anti-cancer drugs do not selectively target cancer cells. Instead, they have the ability 
to kill rapidly dividing cells whilst being relatively non-toxic to resting (non-proliferating) 
cells. Although not ideal, this imparts a certain degree of selectivity because cancer cells are 
constantly dividing whereas the majority of cells in normal tissues are quiescent. In this study 
S. ellipticum leaf crude extract and the positive control cisplatin were screened against 
PBMCs and Chang liver cells to test their level of cytotoxicity against these normal cells. 
PBMCs from normal human donors are convenient to use as a normal cell model but they 
have a limited capacity to proliferate in culture.  Chang liver cells were therefore used in their 
confluent state (non-proliferating) as well as in log phase of their growth curve in order to 
obtain more information from the results. The Cell Titre Blue assay was used for PBMCs 
which are cultured in suspension, while the MTT assay was used for the adherent Chang liver 
cells. 
Figure 4.5 (A) shows the cytotoxic activity of cisplatin against PBMCs in concentrations 
ranging from 1.5 -50 µM. Cisplatin killed more than 50% of the PBMC cells at 12.5, 25 and 
%
 I
n
h
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Figure 4.4: Dose response curves of cytotoxic effect of S. ellipticum against HeLa and MCF-7 cancer cells.  Cells 
were incubated in quadruplicate in the presence of varying concentrations of S. ellipticum crude extract for 48 
hours after which an MTT viability assay was performed. The data was analysed using GraphPad Prism software 
to obtain IC50 values.  IC50 values are reported in Table 4.2.  Data points represent the mean ± SD of quadruplicate 
wells. 
S. ellipticum Log [µg/ml] 
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50 µM. Cisplatin concentrations ranging from 1.5 – 3 µM showed less than 50 % inhibition. 
Figure 4.5 (B) shows the results of the cytotoxic evaluation of S. ellipticum leaf crude extract 
against normal, proliferating Chang liver cells and confluent Chang liver cells. The plant 
showed no inhibitory activity against either the proliferating or the confluent Chang liver 
cells. It seems to have a growth stimulatory effect on the proliferating cells at 16 and 31 
µg/ml. The percentage inhibition seen at 125 µg/ml, which was the highest concentration 
screened, was 40.68 ± 4.99 (SD, n=4). This was significantly lower than its effect on HeLa, 
MCF-7 and PBMCs at the same concentration. 
To obtain the concentration of cisplatin and S. ellipticum required for 50% inhibition in the 
three cancer cell lines, PBMCs and Chang liver cells the IC50 of compounds were determined 
using the log-dose response curve in the GraphPad Prism 4 program. Ideally, S. ellipticum 
should show no or very low cytotoxic activity against the normal cell models or in other 
words the IC50s for normal cells should be higher than that of the cancer cells. Table 4.2 
shows a summary of the IC50 values of cisplatin (positive control) and S. ellipticum against 
HeLa and MCF-7 cancer cell lines and against normal PBMCs and Chang liver cells. The IC 
50 value of cisplatin against HeLa and PBMCs was 7.60 ± 0.39 and 9.91 ± 0.15 µg/ml, 
respectively. The IC50s of cisplatin on the proliferating cells (HeLa, Chang liver) and PBMCs 
with a limited capacity to proliferate were all very similar and lower than its IC50 on non-
proliferating Chang liver cells.   
The IC50 values of S. ellipticum against HeLa, and MCF-7 cancer cells were 88.60 ± 0.03, 
93.03 ± 0.03 µg/ml, respectively. The trend seen with cisplatin with respect to lower IC50 
values on proliferating cells was not observed for the extract. For all further experiments an 
extract concentration of 125 µg/ml was used against these two cancer cell lines, unless stated 
otherwise. S. ellipticum had no inhibitory activity against HT29 cancer cells at 250 µg/ml and 
therefore no IC50 value could be determined. 
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Figure 4.5 Cytotoxic activity of cisplatin and S. ellipticum extract against PBMCs (A) and proliferating and 
confluent Chang liver cells (B). Results represent the mean ± SD of quadruplicate determinations. Cisplatin was 
used as positive control. 
 
Table 4.2: Summary of IC50 values of the cytotoxic effect of cisplatin and S. ellipticum crude 
extract on cancer cells and normal cell models 
 Cisplatin  
(µM) 
S. ellipticum  
(µg/ml) 
HeLa 7.60 ± 0.39 88.60 ± 0.03 
MCF-7 nd 93.03 ± 0.03 
PBMCs 9.91 ± 0.15 77.66  ± 0.14 
Proliferating Chang liver cells 9.85 ± 0.09 > 125 µg/ml 
Confluent Chang liver cells 25.06 ± 0.12 > 125 µg/ml 
nd: not determined 
A 
B 
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4.1.3.2  S. ellipticum fractions and isolated compounds: cytotoxic 
effects 
To determine the active chemical component(s) in the leaf crude extract, responsible for the 
cytotoxic activity in the three different cancer cell lines (Figure 4.2 and Table 4.2), five 
fractions (Table 4.3) were prepared from the crude ethanolic extract. These fractions were 
prepared by a research collaborator at the University of Lagos and kindly supplied for testing. 
Their growth inhibitory activities were evaluated against MCF-7 cancer cells and confluent 
Chang liver cells. The IC50 value of S. ellipticum against MCF-7 was 93.03 µg/ml and 
therefore 62.5 and 125 µg/ml of the fractions were screened. 
 
Table 4.3: List of prepared fractions and isolated compounds from S. ellipticum leaf crude 
extract. 
Plant crude extract Fractions Isolated compounds* 
Sapium ellipticum  (Leaves)  Sc SPE- Petroleum ether - 
SB - Butanolic - 
SAQ – Aqueous  - 
SEA – Ethyl acetate 
SV 2-2a 
SV 2-2b 
SV2-3-3 
Scf - Chloroform 
SCL V2-2 
SCL V2-3 
*Unidentified compounds, only SV 2-2a and SV 2-2b exhibited cytotoxic activity (discussed later) but 
insufficient quantities were isolated for structural elucidation. 
 
The cytotoxic screening results of the fractions as listed in Table 4.4 showed that the 
petroleum ether fraction (SPE) had no cytotoxic activity against MCF-7 cancer cells for both 
concentrations tested. The aqueous fraction (SAQ) had no growth inhibitory activity at 62.5 
µg/ml, but showed more than 50% inhibition at 125 µg/ml. The chloroform (Scf), ethyl 
acetate (SEA) and butanolic (SB) fractions showed more than 50% inhibition for both 
concentrations, with the chloroform fraction having the highest growth inhibitory activity for 
both concentrations. Low to no growth inhibitory activity was seen for all fractions against 
confluent Chang liver cells, except for the chloroform and ethyl acetate fractions at 125 
µg/ml. The butanolic fraction had more than 50% growth inhibitory activity against MCF-7 
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cancer cells, but less than 50% growth inhibitory activity against both proliferating and 
confluent Chang liver cells for both concentrations. 
 
Table 4.4: Summary of cytotoxic screening results (% inhibition) of S. ellipticum fractions 
against MCF-7 cancer cell line and confluent Chang liver cells 
S
. 
el
li
p
ti
cu
m
 l
ea
f 
cr
u
d
e 
ex
tr
a
ct
  
fr
a
ct
io
n
s 
MCF-7 Cells 
 
Confluent Chang liver cells 
62.5 µg/ml 
 
125 µg/ml 62.5 µg/ml 125 µg/ml 
SPE -2.32 ± 6.14 
 
11.29 ± 9.58 6.68 ± 5.05* 16.81 ± 2.70*** 
Scf 79.86 ± 3.20*** 
 
90.86 ± 0.81*** 17.23 ± 8.99* 76.54 ± 7.19*** 
SEA 54.23 ± 7.68*** 
 
65.73 ± 3.83*** 32.00 ± 2.92*** 50.591 ± 0.95*** 
SB 58.87 ± 3.16*** 
 
67.84 ± 4.53*** 10.30 ± 8.96 29.37 ± 1.66*** 
SAQ 6.54 ± 22.56 
 
66.633 ± 3.08*** 32.668 ± 3.36*** 33.496 ± 5.89*** 
Results represent the mean ± SD of quadruplicate determinations. 
Refer to Table 4.3 for description of fraction abbreviations. 
* Significantly different from vehicle control; p < 0.05 
** Significantly different from vehicle control; p < 0.01 
*** Significantly different from vehicle control; p < 0.001 
 
To further determine the active chemical component(s) within the leaf crude extract which 
exerted more than 50% growth inhibitory activity, five compounds were isolated and purified 
from S. ellipticum crude leaf extract (Table 4.3); three from the ethyl acetate (SEA) and two 
from the chloroform (Scf) fraction. Isolation was done by Dr AA Sowemimo from the 
University of Lagos and sent to NMMU for screening. These compounds were screened for 
cytotoxic activity against HeLa, HT29 and MCF-7 cancer cell lines. Note that the leaf crude 
extract has shown low growth inhibitory activity against HT29 cancer cells, and thus no or 
low cytotoxic activity was expected against the cell line. The cytotoxic screening results in 
Table 4.5 show that compounds SV 2-2a and SV 2-2b induced more than 50% growth inhibitory 
activity against the MCF-7 cancer cell line. 
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SV 2-2b showed a growth inhibition of 80.91 ± 2 .86% (SD, n=4) at 31 µg/ml, compared to SV 
2-2a which gave a much lower percentage growth inhibition of 7.28 ± 14.77% at the same 
concentration. The same trend was seen at the higher concentrations tested. SV 2-2b showed 
81.38 ± 1.04 and 89.32 ± 0.84% growth inhibition at 62.5 and 125 µg/ml, respectively, while 
SV 2-2a showed growth inhibition of 58.28 ± 22.69 and 89.92 ± 3.21% at these concentrations. 
Compound SV 2-2b showed more growth inhibitory activity against MCF-7 cancer cell line 
than SV 2-2a. Due to the small amount of compound that was isolated and purified, the whole 
amount was dissolved in DMSO when the stock solution was prepared. Unfortunately the 
compounds were very unstable and lost activity over a short period of time. No further 
cytotoxic screening could be done due to the instability of the compounds. The structures of 
these compounds could furthermore not be elucidated due to the limited amounts available 
and their instability.  
 
 
* Significantly different from vehicle control; p < 0.05 
** Significantly different from vehicle control; p < 0.01 
*** Significantly different from vehicle control; p < 0.001 
 
 µg/ml SV 2-2a SV 2-2b SV2-3-3 SCL V2-2 SCL V2-3 
H
eL
a
 
16 - - -40.38 ± .264 10.66 ± 0.68 1.72 ± 10.09 
31 - - -16.99 ± 9.38 31.88 ± 10.90*** 9.12 ± 12.10 
62.5 - - 1.98 ± .980 21.13 ± 10.35** 20.59 ± 6.84*** 
125 - - 19.52 ± 4.38* 7.39 ± 8.25 2.09 ± 6.84 
H
T
 2
9
 
16 - - 17.70 ± 9.31* 15.04 ± 30.33 11.57 ± 9.23 
31 - - 27.02 ± 4.62*** 17.04 ± 14.13 8.44 ± 7.33 
62.5 - - 39.33 ± 7.21*** -16.26 ± 5.93 5.48 ± 10.47 
125 - - 36.54 ±4.75*** -10.96 ± 18.04 9.22 ± 15.05 
M
C
F
-7
 
16 -22.12 ± 4.39 17.38±10.91* -49.64 ± 19.48  0.21 ± 5.35 3.25 ± 10.18 
31 7.28 ± 14.77 80.91± 2.86*** -57.21 ± 19.09 19.23 ± 6.63* 9.53 ± 11.86 
62.5 58.28 ± 22.69* 81.38± 1.04*** -32.91 ± 31.23 -5.78 ± 0.03 -1.65 ± 4.56 
125 89.92 ± 3.21*** 89.32± 0.84***  27.41 ± 5.53**  18.52 ± 1.92**  0.42± 0.42 
Table 4.5: Summary of cytotoxic screening results (% inhibition) of S. ellipticum isolated compounds 
against HeLa, HT29 and MCF-7 cancer cells  
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Very low growth inhibition was seen for SV2-3-3, SCL V2-2 and SCL V2-3 in HeLa, HT29 and 
MCF-7 cancer cell lines and in fact at some concentrations these compounds stimulated 
growth, as represented by the negative percentage growth inhibition in Table 4.5. 
 
4.1.4 Cytotoxic screening of Combretum paniculatum against HeLa, 
HT29 and MCF-7 cancer cells 
C. paniculatum leaf crude extract was potentially cytotoxic against HeLa cells showing over 
50% activity at 250 µg/ml (Figure 4.1). The activity was much lower against MCF-7 and 
HT29 cells (Figure 4.2), suggesting possible selectivity for specific cell types, in this case 
cervical cancer cells. Bioassay guided fractionation was performed with the assistance of Dr 
AA Sowemimo. Fractions and isolated compounds of C. paniculatum (Table 4.6) were 
prepared in her laboratory and screened at NMMU against HeLa, HT29 and MCF-7 cells 
using the MTT assay and against PBMCs using the Cell Titre Blue assay. A concentration 
range of 62.5, 125 and 250 and 500 µg/ml was tested to determine the degree of cytotoxicity. 
 
Table 4.6: List of fractions and isolated compounds prepared from crude ethanolic C. 
paniculatum leaf extract.  
Plant crude extract Fractions Isolated 
Compounds 
Isolated 
Compounds Name 
Combretum paniculatum Cpl (Aq) - Aqueous - - 
Cpl (PE) - Petroleum ether - - 
Cpl (ET) - Ethyl acetate Cpe 4-4 Pheophorbide 
Cpe 3-4 Pheophorbide a methyl 
ester 
Cpe 4-9 Not pure 
 
Figure 4.6 (A) Shows the cytotoxic results of the three C. paniculatum fractions Cpl (Aq), 
Cpl (PE) and Cpl (ET) against HeLa, HT 29 and MCF-7 cancer cells. Cisplatin at 10 and 100 
µM inhibited HeLa, HT 29 and MCF-7 cell proliferation by >75%. All three fractions 
exhibited cytotoxicity but only the ethyl acetate fraction (ET) inhibited cell proliferation in all 
three cell lines by more than 50% at all three concentrations tested. Interestingly, the trend 
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observed with the crude extract of being more toxic to HeLa cells than MCF-7 and HT29, 
was not seen with the fractions. 
Figure 4.6 (B) shows the dose-dependent cytotoxic effect of the isolated compounds Cpe 4-4, 
Cpe 3-4 and Cpe 4-9 of C. paniculatum. The first two caused significant inhibition of all 
three cell lines at all the concentrations tested (p < 0.001 except Cpe 3-4 against HT29 with p 
< 0.01). Chemical analysis of Cpe 4-9 revealed that it was not pure and contained a number 
of contaminating compounds.  Its cytotoxic activity was lower than that of Cpe 4-4 and 
comparable to Cpe 3-4 and it was decided not to purify it further. 
For Cpe 4-4, it was only at the lowest concentration of 62.5 µg /ml on HT29 cells that it was 
not able to inhibit proliferation by >50%. A similar trend was observed for Cpe 3-4, except 
that the % inhibition of HT29 cells was <50% at both 62.5 and 125 μg/ml.  
Results from the Cell Titre Blue assay on PBMCs (Figure 4.7) suggest that Cpe 3-4 was less 
toxic to normal cells than Cpe 4-4. Low toxicity was also seen with Cpe 4-9. 
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Figure 4.6: Cytotoxicity of C. paniculatum fractions (A) and isolated compounds (B) against HeLa, HT29 and 
MCF-7 cancer cells. Results represent the mean ± SD of quadruplicate determinations. Cisplatin was used as 
positive control. Cpe4-4, Cpe 3-4 and Cpe 4-9 are as listed in Table 4.2. Significantly different from vehicle 
control; p < 0.05; ** Significantly different from vehicle control; p < 0.01; # Significantly different from vehicle 
control; p < 0.001 
 
 
 
 
A 
B 
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Figure 4.7: Cytotoxic activity of compounds isolated from C. paniculatum leaf extract against PBMCs.  Results 
represent the mean ± SD of quadruplicate determinations. Cisplatin was used as positive control. Cpe4-4, Cpe 3-4 
and Cpe 4-9 are as listed in Table 4.2. * Significantly different from vehicle control; p < 0.05; ** Significantly 
different from vehicle control; p < 0.01; *** Significantly different from vehicle control; p < 0.001 
 
 
 
4.2 Screening of 17 plant extracts for hTERT inhibition  
The nearly universal expression of telomerase reported in almost all human cancer cells but 
not in most normal cells, provides an attractive target for the treatment of cancer [81]. 
Inhibition of the enzyme can be achieved through the design of telomerase inhibitors or the 
suppression of telomerase expression. In this study we used a cellular immunofluorescence -
based hTERT flow cytometry assay to measure the amount of the catalytic subunit of the 
telomerase enzyme present after exposure to the 17 plant extracts at 12.5 and 125 µg/ml for 
24 and 48 hours. The levels of the two internal reference proteins GAPDH and β-actin, were 
measured in the same samples to validate the results found for the measurement of the 
catalytic subunit of telomerase.  
Flow cytometry is a convenient method that allows one to record data for thousands of 
individual cells in as little as a few seconds.  Figure 4.8 (A) shows an example of a 2D dot 
plot of U937 vehicle control cells (treated with 0.15% DMSO). Each dot represents a single 
cell passing through the laser beam of the flow cytometer. The position of each dot represents 
its forward scatter (FS) and side scatter (SS) properties, which relate to size and cell 
granularity, respectively. Based on the FS and SS, a region can be drawn around a sub 
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population to isolate events for analysis. The data of all the events within the region can then 
be displayed in subsequent plots by gating on the region. In this case the fluorescence 
properties of the cells in region A are displayed in a histogram (Figure 4.8 B).  
 
Figure 4.8: Recording of flow cytometry data showing vehicle control cells as example. (A) Detection of cells in 
region A on 2D dot plot of forward (FS)- vs side (SS)-scatter and (B) a histogram representing the fluorescence 
properties of the cells in region A. Cells were labelled with anti-hTERT primary and FITC-conjugated 
secondary antibodies for detection of hTERT, the catalytic subunit of telomerase. A minimum of 10 000 events 
were recorded per sample on a Beckman Coulter FC500 (Miami FL, USA) flow cytometer. 
 
Histograms of control cells can be compared to that of treated cells by observing their relative 
positions on a histogram overlay. To illustrate this, Figures 4.9 and 4.10 show the overlay 
histograms of hTERT and β-actin levels in U937 cancer cells after 24 hours of treatment with 
12.5 and 125 µg/ml for the five extracts investigated in Section 4.1.2. The grey shaded area 
represents the isotype control antibody which distinguishes the non-specific binding. The 
black histogram represents the control cells (black line), the red histogram cisplatin (50 µM) 
and P1-P5 at 12.5 µg/ml and 125 µg/ml are represented by the different colours as indicated 
in the figure captions. A decrease in hTERT levels will cause the histogram to appear to the 
left on the log scale when compared to the control cells (i.e. lower fluorescence intensity due 
to less antigen available for the antibody to bind to). Similarly, an increase in the levels of 
hTERT will cause the histogram to appear to the right, at higher fluorescence intensities than 
that of the control cells.  
The flow cytometry protocol was set up to record 10 000 events for each sample and 
therefore the histograms were expected to all have the same peak areas. In Figure 4.9 the low 
concentration exposure for 24 hours for cisplatin showed a smaller peak when compared to 
the control and plant treatments. This can be explained by cisplatin’s known apoptosis 
inducing properties, through binding to nuclear DNA and subsequently interfering with DNA 
A B 
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replication mechanism. Fewer cells are present in the sample due to elimination via 
apoptosis.  
Figure 4.9 shows the overlay histograms of the effect of P1-P5 on hTERT protein 
measurement. At the higher concentration, P1, P2 and P3 appeared to have reduced the levels 
of hTERT relative to the vehicle control cells. In order to quantify these changes, and to 
allow better interpretation of the results, one can compare the mean fluorescence intensities 
obtained from these histograms. The results of all 17 plant extracts are summarized in Table 
4.7. In order to simplify interpretation, mean fluorescence intensity values for hTERT that 
were one or more fluorescence unit lower than the control value, were indicated in bold italic 
font. Such values suggest a reduction in the levels of hTERT due to the treatment with the 
plant extract. After 24 hours cisplatin caused an unexpected increase in hTERT expression, 
however for 48 hours at 12.5 µg/ml and 24 and 48 hours at 125 µg/ml, cisplatin showed a 
decrease in hTERT protein measurement as was expected. At the low extract concentration at 
24 hours no significant changes in hTERT protein measurement were seen when compared to 
the control cells. At 48 hours a few plant extracts seemed to have caused a decrease in 
hTERT protein measurement. At 125 µg/ml for both 24 and 48 hours the following plant 
extracts, 4, 5, 9, 11, 13, 14 and 16 caused a reduction in mean fluorescence intensity of one 
unit or more when compared to the control cells.  The plants from which these extracts 
originated were P. lappacea, J. extensa, L. nigritana, C. molle, L. acida, C. achyranthoides 
and C. prostrata.  
The possibility that reductions in hTERT levels were due to non-specific inhibition of gene 
transcription or protein synthesis and therefore not specifically targeted at hTERT expression 
or synthesis cannot be excluded. Such a general, non-specific effect would not have any 
therapeutic use. By quantifying one or more reference proteins in the same cells in which 
hTERT levels were measured, one would be able to validate the results and observe any 
possible non-target effects. This approach is similar to that employed in molecular biology 
where genes widely known as housekeeping genes are used to account for experimental error 
as opposed to biological differences [132]. GAPDH, an enzyme of glycolysis and β-actin, a 
cytoskeletal protein, were considered possible reference protein candidates for this study. 
They were selected on the assumption that their levels of expression would be unaffected by 
experimental conditions [133]. The internal reference gene GAPDH showed poor 
inconclusive results (not shown) and further analysis with the enzyme was stopped.  
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Figure 4.10 shows the overlay histograms of internal reference protein β-actin levels in U937 
cancer cells for 24 hours at 12.5 and 125 µg/ml. The grey shaded area represents the isotype 
control antibody which distinguishes the non-specific binding. The black histogram represent 
the control cells (black line), cisplatin (50 µM) is represented by the red line and results from 
the selected five plant extracts at 12.5 and 125 µg/ml are represented by the different 
coloured lines as indicated in the figure caption. The same negative and positive control cells 
were used for 12.5 and 125 µg/ml. The reference protein levels should be unaffected by the 
different treatments, however cisplatin treatment after 24 and 48 hours caused a shift to the 
right as seen in the overlay histograms with an x-mean value of 6.57 and 26.4 when 
compared to the x-mean value of 5.0 of the control cells. Table 4.7 summarizes the mean 
fluorescence intensities of the β-actin protein measurement results of 17 plant extracts after 
24 hours of treatment.  Only cisplatin was tested at 48 hours.  It is clear that the levels of this 
protein were affected by some of the treatments, especially by cisplatin at 48 hours where a 
large increase was observed. 
Other researchers have reported increases of at least three times in mitochondrial β-actin 
levels of apoptotic cells [134]. The large increase in x-mean from 3.8 to 26.4 observed in the 
present study could be explained by β-actin antibody binding the cytosolic, nuclear and 
accumulated mitochondrial β-actin. Another study revealed that both GAPDH and β-actin 
mRNA levels vary with cellular proliferation and thus variability in expression emphasises 
their important physiological roles [133]. It is of great importance that the concentrations of 
the reference protein should not be influenced by drug treatment and other proteins will have 
to be considered for validation of the hTERT results in this study.   
To further validate the results from this screening experiment, more replicates of each sample 
would be required. In order to minimise the number of samples for practical reasons, only 
one sample was analysed for each extract. Within this one sample, a minimum of 10 000 cells 
were analysed but this result would not reflect experimental variation that may occur between 
replicate samples. 
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Figure 4.9: Histograms of hTERT protein expression in U937 cancer cells treated with P1- S. ellipticum, P2- C. 
paniculatum; P3- C. trigyna; P4- D. cordata; P5- C. prostrate at 12.5 and 125 µg/ml for 24 hours. Cisplatin was 
used as positive control at 50µM (red histogram). Shaded histogram: isotype control; black: 0.125% DMSO; 
others colours: plant extracts.  After treatment, cells were fixed and permeabilised and hTERT was labelled 
using a primary anti-hTERT and FITC conjugated secondary antibody.  A minimum of 10 000 cells per sample 
were analysed on a flow cytometer.  
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Figure 4.10: Histograms of internal reference protein β-actin expression in U937 cancer cells  treated with P1- S. 
ellipticum, P2- C. paniculatum; P3- C. trigyna; P4- D. Cordata; P5- C.a prostrata.at  at 12.5 and 125 µg/ml for 
24 hours. Cisplatin was used as positive control at 50 µM (red histogram). Shaded histogram: isotype control; 
black: 0.125% DMSO; others colours: plant extracts.  After treatment, cells were fixed and permeabilised and β-
actin was labelled using a primary anti- β-actin and FITC conjugated secondary antibody.  A minimum of 10 
000 cells per sample were analysed on a flow cytometer. 
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N
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hTERT 
X-Mean 
β-Actin 
X-Mean 
12.5 µg/ml 125 µg/ml 12.5 µg/ml 125 µg/ml 
24 H 48 H 24 H 48 H 24 H 48 H 24 H 48 H 
Control 5.29 6.61 6.3 7.16 5.00 3.8 5.00 3.8 
Cisplatin 8.55 5.21 4.05 4.57 6.57 26.4 6.57 26.4 
1a – P1 7.76 5.02 5.41 5.88 6.91 - 5.89 - 
1b 6.44 8.94 6.27 6.1 6.74 - 6.32 - 
2– P2  4.17 6.17 4.97 6.24 5.96                              - 5.68 - 
3 – P3 6.83 7.13 4.59 6.34 3.72 - 4.85 - 
4 5.58 7.03 1.65 5.42 7.48 - 5.75 - 
5 5.55 12.88 3.38 5.94 7.03 - 5.83 - 
6 8.09 12.2 6.73 4.98 5.53 - 3.75 - 
7 7.36 6.04 5.32 6.41 4.7 - 5.66 - 
8 9.01 6.18 6.19 4.51 4.93 - 2.74 - 
9 5.61 6 5.03 4.11 3.07 - 5.05 - 
10 5.87 5.5 5.39 5.35 5.25 - - - 
11 5.97 6.35 4.53 5.27 5.23 - 6.81 - 
12 5.34 6.83 5.55 5.46 4.99 - 9.34 - 
13 7.1 4.87 5.02 5.44 5.46 - 4.33 - 
14 5.69 4.61 5.23 5.73 6.67 - 4.46 - 
15 – P4 5.41 4.57 5.6 5.43 4.36 - 3.55 - 
16 - P5 5.97 4.99 5.3 3.69 5.59 - 4.48 - 
Table 4.7: List of hTERT and β-Actin x-mean expression results of the 17 plants screened       
against U937 cancer cells 
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4.3 Mechanism of action of selected extracts and compounds 
In view of the promising cytotoxic effects observed for S. ellipticum and C. paniculatum and 
the compounds isolated from them (sections 4.1.3 and 4.1.4) as well as the indication that the 
crude extracts of these two plants might reduce hTERT levels (section 4.2), it was decided to 
do further investigation into their modes of action.   
 
4.3.1 S. ellipticum crude extract 
The crude extract of S. ellipticum was chosen to investigate the mode of action because of the 
loss of the two active compounds due to instability (Section 4.1.3.2).   
4.3.1.1 Cell cycle analysis 
A phenomenon that plays a key role in cancer therapy is cell cycle arrest [135]. The cell cycle 
is a target for many anticancer drugs, where naturally occurring or synthetic molecules with 
anticancer activity effects basal cell cycle control mechanisms [135, 136]. To establish 
whether S. ellipticum leaf crude extract inhibited cell growth by blocking cells in a certain 
phase of the cell cycle or whether it induces apoptosis, HeLa, HT29 and MCF-7 cancer cells 
were exposed to 125 µg/ml of the crude extract for 6, 16, 24 and 48 hours after which DNA 
cell cycle analysis was performed.  
The acquisition protocol on the flow cytometer was set up to record FS and SS as explained 
in the previous section (Figure 4.8.A). Once the cell population of interest has been 
identified, a plot of FL3 peak area vs FL3 peak height was used to eliminate any doublets or 
cell clumps (Figure 4.11.A).  A region was drawn around the cells of interest. The histogram 
of fluorescence intensity (FL3), plotted on a linear scale as opposed to the log scale in the 
previous section, was then gated on the region. An example of such a gated histogram is 
shown in Figure 4.11.B. The peak marked “A” often represents apoptotic cells and is referred 
to as the sub-G1 peak. Apoptotic cells show up in the sub-G1 peak due to DNA 
fragmentation occurring during apoptosis and loss of small fragments of DNA from the 
permeabilized cells.  Less PI will therefore bind to these cells [137]. In the G1/G0 phases, 
cells have one copy of DNA (diploid; 2N) and form a sharp peak labelled “B” in Figure 4.11 
B.  Cells in G2 or M phase, with two copies of the DNA (tetraploid; 4N) show up in a peak at 
fluorescence intensity almost double that of G1/G0 as indicated by region “D” while the S-
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phase cells having an amount of DNA between  2N and 4N form a “valley” (region “C”) 
between these two peaks. The histogram shown in Figure 4.11 was obtained from the FC500 
Beckman Coulter software.  The regions indicating the different phases and percentage of 
cells in each phase are not very accurate and can be calculated more accurately by using 
software that accounts for the overlap of the different peaks. In this study, MultiCycle 
software was used for this purpose. 
 
 
Figure 4.11: Recording of flow cytometry data for cell cycle analysis showing HeLa vehicle control cells as 
example. (A) Detection of DNA in the linear region on a 2D dot plot of peak area of the electronic signal 
reaching the photomultiplier tube vs peak height; and (B) histogram representing the fluorescence properties of 
the cellular DNA in different phases of the cell cycle within the linear region of A. Cells were permeabilized 
and stained with PI. A minimum of 10 000 events were recorded per sample on a Beckman Coulter FC500 flow 
cytometer (Miami FL, USA). 
 
The results for HeLa cells in Figure 4.12 show that cisplatin at 12.5 µM caused an 
accumulation of cells in the S phase compared to control cells after only 6 hours of exposure. 
Cells further accumulated in the S phase after 16 hours with a large increase in the size of the 
sub-G1 peak, corresponding to apoptotic cells. After 24 hours a large sub-G1 peak, 
corresponding to apoptotic cells, was still observed with an accumulation of cells in the 
G2/M phase. Further accumulation of cells in the G2/M phase and an even larger peak are 
 A B 
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seen in the sub-G1 phase after 48 hours. S. ellipticum treatment (125 µg/ml) caused 
accumulation of HeLa cells in the G2/M phase when compared to control cells after 16 hours. 
After 48 hours, cells accumulated in the G1/G0 phase by 66.2% compared to 40% of the 
control cells. S. ellipticum slightly increased the cells in the G1/G0 phase over the 6 to 24 
hours exposure time, while after 48 hours a 23.45% increase was noted. It seems that the cells 
were being blocked in the G1/G0 phase of the cell cycle. It would be interesting to see the 
percentage of cells in the G1/G0 phase after 60 and 72 exposure times.  
The cisplatin results for HT29 in Figure 4.13 show a similar trend as seen with HeLa cells, 
with the percentage cells in S phase increasing relative to the control. S. ellipticum treatment 
caused cells to start to accumulate in the G1/G0 phase after 16 hours of treatment. A further 
accumulation of cells in the G1/G0 phase was seen, with accumulation of cells in the G2/M 
phase. After 48 hours there was a slight increase in the percentage of cells in the G1/G0 
phase, with more cells accumulating in the G2/M phase. The extract appears to have a dual 
effect. 
The effect of cisplatin on MCF-7 cells was again induction of S phase arrest with an 
accompanying increase in the size of the sub-G1 peak (Figure 4.14).  S. ellipticum treatment 
caused no significant changes in the cell cycle phases over the exposure time up to 24 hours. 
Only after 48 hours did cells accumulate in the G2/M phase of the cell cycle. A large peak 
corresponding to possibly apoptotic cells could be seen as a sub-G1 peak for both 24 and 48 
hours when compared to control cells. It seems that S. ellipticum caused a G2/M phase arrest 
in the MCF-7 cancer cells, by blocking the cells in this phase of the cell cycle. 
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Figure 4.12: Cell cycle analysis of HeLa cells treated with S. ellipticum leaf extract for 6, 16, 24 and 48 hours. 
HeLa cells were treated with 0.125% DMSO (control), 12.5 µM cisplatin as positive control and 90 µg/ml of S. 
ellipticum leaf extract.  Data from 10 000 cells in each sample was recorded and analysis performed using 
MultiCycle software. 
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Figure 4.13: Cell cycle analysis of HT29 cells treated with S. ellipticum leaf extract for 6, 16, 24 and 48 hours. 
HT29 cells were treated with 0.125% DMSO (control), 12.5 µM cisplatin as positive control and 90 µg/ml of S. 
ellipticum leaf extract.  Data from 10 000 cells in each sample was recorded and analysis performed using 
MultiCycle software. 
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Figure 4.14: Cell cycle analysis of MCF-7 cells treated with S. ellipticum leaf extract for 6, 16, 24 and 48 hours. 
MCF-7 cells were treated with 0.125% DMSO (control), 12.5 µM cisplatin as positive control and 90 µg/ml of S. 
ellipticum leaf extract.  Data from 10 000 cells in each sample was recorded and analysis performed using 
MultiCycle software. 
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4.3.1.2 Mechanism of Cell Death: apoptosis or necrosis 
The increases observed in the sub-G1 peak with cisplatin and S. ellipticum in the previous 
section prompted further investigation into the possibility of apoptosis induction. Although 
the presence of a sub-G1 peak may indicate the presence of apoptotic cells, it is not a 
conclusive result and needs to be verified with a more specific apoptosis assay such as the 
Annexin V assay. The three cell lines used in the previous sections are adherent and not ideal 
for the Annexin V assay. Early in apoptosis, cells lose their phospholipid membrane 
asymmetry and expose PS at the cell surface while maintaining their plasma membrane 
integrity. This results in the exclusion of dyes such as PI. Damage to adherent cells during 
collection with trypsin and EDTA, either in combination or separately allow access of 
annexin V-FITC to internally located PS, and, hence giving false positive results [138]. For 
this reason, a suspension cancer cell line, U937 histiocytic lymphoma, was used to establish 
whether the mode of cell death induced by the plant extract was apoptotic or necrotic.  
The flow cytometry protocol is set up to record and plot FS and SS on a 2D dot plot as 
described previously (section 4.2). The cells are located on this dot plot and marked by 
drawing a region around them. Further plots, described below, are gated on this region.  
Annexin V-FITC binds and stains PS which is translocated from the inner- to the outer layer 
of the plasma membrane at the early stages of apoptosis. Since the cells are not permeabilised 
during the staining protocol, PI will only enter cells with compromised membrane integrity, 
usually necrotic cells. However, as the apoptotic process progresses in vitro in the absence of 
the immune system, cell membrane integrity is lost and both PI and Annexin V-FITC can 
stain these cells. The results are typically plotted on a 2D dot plot with log of PI fluorescence 
(FL3) on the y-axis and log of Annexin V-FITC fluorescence (FL1) on the x-axis.  Live cells 
will not stain with either PI or Annexin V-FITC (PI
-
 and Annexin V-FITC
-
); necrotic cells 
will stain positive for PI only (PI
+ 
and Annexin V-FITC
-
); early apoptotic cells will be PI
-
 and 
Annexin V-FITC
+
 and finally, late apoptotic cells will be PI
+ 
and Annexin V-FITC
+
. Once the 
results have been recorded, the flow cytometer software is used to do electronic colour 
compensation. This is necessary because of the overlapping fluorescence emission spectra of 
the two dyes. 
To investigate the mode of cell death in U937 suspension cancer cells after 24 hours of 
treatment with cisplatin and S. ellipticum, cells were stained with Annexin V-FITC and PI. 
The results are shown in Figure 4.15. Cisplatin at 5 µM increased the percentage apoptotic 
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cells (quadrant A4) by 12.2% compared to the vehicle control cells. Figure 4.15 C shows the 
results of U937 treated with a higher concentration of cisplatin (50 µM). The apoptotic cells 
increased to 31.7% while an increase in the secondary necrotic (late apoptotic) cells was also 
observed. As explained previously, this might be due to the fact that no phagocytosis takes 
place in vitro and as the apoptotic process progresses, cell membrane integrity is lost, so that 
PI can enter cells and stain the DNA. Figure 4.15.D shows the results of U937 cells treated 
with 125 µg/ml S. ellipticum. The plant extract caused only a small increase in apoptosis from 
2.3% to 4.1% when compared to the positive control cells. These results conclude that S. 
ellipticum does not cause apoptosis in the U937 cancer cells. 
 
 
Figure 4.15: Flow cytometry analysis of apoptosis by Annexin V-FITC (x-axis) and propidium iodide (y-axis) 
staining. (A) Vehicle control cells, (B) Positive control cisplatin at 5 µM, (C) Positive control cisplatin at 50 µM 
and (D) S. ellipticum at 125 µg/ml.  A minimum of 10 000 events were recorded for each sample.  The 
experiment was done in duplicate and a representative plot of each treatment is shown. 
 
 
 
 
  
A B 
 C D 
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4.3.2 Compounds isolated from C. paniculatum  
4.3.2.1 Cell cycle analysis 
HeLa cells were used to establish whether the purified compounds (Cpe 4-4, Cpe 3-4) induce 
cell cycle arrest. Cisplatin at 50 µM typically caused an accumulation of the cells in the S 
phase after 48 hours of treatment (Figure 4.16). A large increase in the size of the sub-G1 
peak, corresponding to apoptotic cells, can already be seen after 24 hours of cisplatin 
treatment and the effect was more pronounced after 48 hours. The two isolated compounds 
both induced cell cycle arrest in the G1/G0 phase. Although Cpe 4-4 was more toxic to HeLa 
cells, Cpe 3-4 caused a more enhanced effect on the cell cycle after 24 hours. In comparison 
with the control cells where 38.5% of the cells were found in the G1/G0 phase, 70% of Cpe 
3-4 and 55.9% of Cpe 4-4 treated cells have accumulated in the G1/G0 phase (Figure 4.17) 
After 48 hours of treatment, around 80% of the cells were arrested in the G1/G0 with both 
compounds. Interestingly, the sub-G1 peak did not increase with either of the two 
compounds, even after 48 hours. The cell cycle arrest results revealed that the two 
compounds act in a very similar way through induction of cell cycle arrest in the G1/G0 
phase. No increase was observed in the sub-G1 (apoptotic) peak and therefore it would 
appear as if the reduction in viable cell numbers compared to control treated cells was due to 
inhibition of proliferation rather than cytotoxicity.  
The two compounds were identified by Dr Sowemimo and collaborators from Beijing, China 
as pheophorbide a (Cpe 3-4) and pheophorbide a methyl ester (Cpe 4-4). This is the first 
report on these two compounds, from C. paniculatum and the induction of cell cycle arrest in 
HeLa cells in the absence of photoactivation. Our results further suggest that the methyl ester 
is a more potent inhibitor of proliferation than pheophorbide a in at least two of the three cell 
lines investigated. It was interesting and encouraging to see that the pheophorbide a was more 
cytotoxic than its methyl ester to PBMCs isolated from normal human blood cells. 
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Figure 4.16: Cell cycle analysis of HeLa cells treated with compounds for (A) 24 hours and (B) 48 hours. HeLa 
cells were treated with 0.125% DMSO (vehicle control), 50 µM cisplatin as positive control, 62.5 µg/ml of 
pheophorbide a (Cpe4-4) or pheophorbide a methyl ester (Cpe3-4).  Data from 10 000 cells in each sample was 
recorded and analysis performed using MultiCycle software. 
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4.4 Cytotoxic screening of two more medicinal plant species 
The research done for this project formed part of an ongoing African Laser Centre-funded 
collaboration between researchers from the Nelson Mandela Metropolitan University in Port 
Elizabeth, South Africa and the University of Lagos in Lagos, Nigeria.  After screening of the 
first 17 extracts was complete, Dr Sowemimo supplied us with another two crude extracts 
from two plant species for screening. The plants were U. chamae and L. cupanioides.  One of 
these, L. cupanioides was fractionated, the fractions screened and the most active fractions 
identified for further investigation by another student. The cytotoxicity results obtained for 
these crude extracts and fractions against HeLa, HT29 and MCF-7 cells are reported in this 
section. 
Figure 4.17 shows the cytotoxic results of U. chamae and L. cupanioides crude extracts 
against HeLa, HT29 and MCF-7 cancer cell lines. Cisplatin at 10 µM inhibited growith by 
77.14 ± 2.84, 51.81 ± 6.99 and 75.00 ± 2.76 µg/ml (SD, n=4) for HeLa, HT29 and MCF-7 
respectively. U. chamae gave 50% growth inhibition at 125 µg /ml against HeLa and MCF-7 
cancer lines. U. chamae showed very little growth inhibition against HT29 cancer cell line 
compared to HeLa and MCF-7 cells. This seemed to be the trend with most of the plant 
extracts. L. cupanioides root extract (LR) showed no inhibitory activity against the three cell 
lines for both 62.5 and 125 µg/ml. However it seems at 62.5 µg/ml the root extract stimulated 
growth in the MCF-7 cancer cell line. L. cupanioides leaf extract (LL) showed inhibitory 
activity against HeLa and MCF-7 cancer cell lines, with the greatest inhibitory effect against 
HeLa cells, where both 62.5 and 125 µg/ml gave more than 50% inhibition. U. chamae and L. 
cupanioides (leaf and root) extracts had no cytotoxic activity against the HT29 cell line.  
As mentioned above, L. cupanioides leaf crude extract (LL) had no growth inhibitory activity 
against the HT29 cancer cell line. Results in Table 4.8 show that of the fractions prepared 
from LL, only the ethyl acetate fraction b (ETb) at 250 µg/ml was able to inhibit HT29 
proliferation by more than 50%.  
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Figure 4.17: Screening results of U. chamae and L. cupanioides leaf (LL) and root (LR) extract against HeLa, 
HT29 and MCF-7 cancer cells. Results represent the mean ± SD of quadruplicate determinations. Cisplatin was 
used as positive control. 
 
The aqueous fraction showed no inhibitory activity at or above 50%. The butanolic fraction 
inhibited both HeLa and MCF-7 cancer cell lines, showing greater activity against HeLa at 
250 µg/ml, but having no activity at 125 µg/ml. Ethyl acetate a and b fractions showed 
growth inhibitory activity against both cell lines, with both fractions showing greater activity 
against the Hela cancer cells, however fraction b failed to inhibit the HeLa cells with the 
lower concentration, but inhibited growth in the MCF-7 cancer cells over all concentrations 
tested. 
These two fractions, LL(Eta) and LL(Etb) were tested further by another student and shown 
to induce growth arrest in the G1/G0 phase which culminates in apoptosis induction 
(unpublished results). 
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 [Extract] 
(μg/ml) 
LL 
(Aq) 
LL 
(B) 
LL 
(Etb) 
LL 
(Eta) 
LL 
 (H) 
LL  
(Cl) 
LL  
(M) 
H
eL
a
 
62.5 -34.47 ± 
15.07 
-10.89 ± 
6.54 
33.83 ± 
14.62* 
56.79 ± 
3.51*** 
-15.41 ± 
6.48 
-22.89 ± 
15.20 
-44.29 ± 
8.69 
125 0.95 ± 
10.58 
33.62 ± 
6.35** 
54.14 ± 
7.82*** 
56.74 ± 
3.71*** 
9.57 ± 
3.06 
5.83 ± 
4.331 
41.0 ± 
1.65** 
250 43.44 ± 
6.68** 
73.20 ± 
4.95*** 
82.55 ± 
1.28*** 
83.43 ± 
1.60*** 
34.66 ± 
2.55** 
41.93 ± 
5.01** 
82.34 ± 
2.73*** 
H
T
 2
9
 
62.5 -4.26 ± 
9.39 
6.10 ± 
8.11 
40.91 ± 
3.40*** 
9.97 ± 
4.32* 
31.42 ± 
20.89* 
3.99 ± 
7.28 
-16.645 ± 
8.03 
125 -2.35 ± 
12.11 
42.20 ± 
3.87*** 
16.53 ± 
8.90* 
19.11 ± 
4.81** 
12.78 ± 
7.47* 
19.81 ± 
5.07** 
-11.61 ± 
9.85 
250 9.85 ± 
4.65 
42.56 ± 
9.48*** 
51.11 ± 
5.47*** 
31.65 ± 
3.72*** 
34.58 ± 
4.85*** 
17.82 ± 
4.56** 
-15.24 ± 
9.99 
M
C
F
-7
 
62.5 -3.46 ± 
10.82 
20.53 ± 
12.39 
60.38 ± 
2.81*** 
57.49 ± 
2.71*** 
-8.65 ± 
12.08 
1.37 ± 
11.69 
-30.93 ± 
15.43 
125 37.03 ± 
21.30* 
62.39 ± 
4.48*** 
65.06 ± 
5.09*** 
50.65 ± 
4.14*** 
7.35 ± 
10.76 
-14.34 ± 
35.49 
37.54 ± 
7.61** 
250 71.61 ± 
3.88*** 
57.64 ± 
5.66*** 
67.63 ± 
3.88*** 
68.95 ± 
4.19*** 
60.36 ± 
9.93*** 
41.50 ± 
7.54* 
63.69 ± 
3.95*** 
Table 4.8: Cytotoxic screening results (% inhibition) of L.cupanioides fractions against HeLa, 
HT29 and MCF-7 cancer cells 
 
LL – L.cupanioides leaf crude extract was fractionated using the following solvents:, Aq-Aqueous (water), B- 
butanol, Et- ethyl acetate, H- hexane, Cl- chloroform and M -methanol.  Two fractions, a and b, were collected for 
the ethyl acetate elution. 
* Significantly different from vehicle control; p < 0.05 
** Significantly different from vehicle control; p < 0.01 
*** Significantly different from vehicle control; p < 0.001 
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Chapter 5: Discussion and conclusion 
The 16 plants in this study are being used in South-Western Nigeria for the management of 
cancer by traditional medical practitioners. However the main problem facing the use of 
traditional medicines is the proof requirement that the active compounds contained in the 
medicinal plants are useful, safe and effective [101].  
Of 16 plants screened for in vitro anticancer activity against HeLa cancer cells, C. molle 
leaves, A. parvoniana fruit, and L. acida stembark were non toxic. However, C. molle leaves 
showed a decrease of one or more than one fluorescence unit in the level of hTERT protein at 
125 µg/ml for both 24 and 48 hours when compared to the control cells. Research has shown 
that the alcoholic extracts of leaves and water extracts of C. molle twigs have capacity to 
reduce sarcoma tumours in animals [139]. This effect may be explained by the hTERT 
inhibition observed in the present study. 
Previously, researchers have reported that only the root and stembark of A. parvoniana has 
cytotoxic activity [115] and the absence of toxicity in the fruit extract is therefore not 
surprising. No published research was found on anticancer activity of L. acida stembark 
although in the current study the plant extract showed a decrease in hTERT levels at the 
higher concentration for 48 hours.  
P. lappacea, J. extensa stembark, S. ellipticum stembark, A. sessilis, L. nigritana stembark 
and C. zenkeri root were moderately toxic, inducing less than 40% inhibition of cell growth 
in HeLa cells at 500 µg/ml. With the exception of S. ellipticum stembark, all these extracts 
reduced hTERT staining by one or more than one fluorescence unit when compared to the 
control cells at 125 µg/ml for 24 and 48 hours, suggesting reduced hTERT expression and 
telomerase activity.   
A literature search of previously published work on the plants with moderate cytotoxicity 
yielded the following: dichloromethane and methanol extracts of P. lappacea has shown 
cytotoxic effects with IC50 values of 66.5 and > 100 µg/ml and 68.3 and > 100 µg/ml against 
J774 and W138, respectively and aqueous extract with IC50 values > 100 µg/ml against both 
cell lines [140]. Ethanolic extracts of A. sessilis were reported to significantly reduce 
pancreatic adenocarcinoma Panc-1 cell proliferation with an IC50 of 27 μg/ml [141]; however 
another publication showed no cytotoxic activity against HeLa cells [142]. No published 
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research on anticancer activity of J. extensa, S. ellipticum, L. nigritana or C. zenkeri root 
could be found.  
E. conyzoides leaves, H. barteri leaves C. achyranthoides were moderately toxic, inhibiting 
HeLa cell growth by 40-50% at 500 µg/ml. No publications of any cytotoxicity or telomerase 
inhibitory activity of these three plants has previously been recorded; however they too 
showed one or more than one fluorescence unit less hTERT protein expression when 
compared to the control cells at 125 µg/ml for 24 and 48 hours.  
Extracts with the best potential toxicity against HeLa cells were S. ellipticum leaves, C. 
paniculatum, C. trigyna, D. cordata and C. prostrata, showing over 50% inhibitory activity 
at 500 µg/ml. Only S. ellipticum leaves showed one or more than one fluorescence unit less 
hTERT protein expression when compared to the control cells at 125 µg/ml for 24 and 48 
hours. The other four extracts showed a decrease in one or more than one fluorescence unit 
for either 24 or 48 hours at one of the tested concentrations. Even though these plants showed 
over 50% cytotoxic activity against HeLa cells, no publications about possible anticancer 
activity was found in the literature. Further screening of these five plant extracts against 
MCF-7 cancer cells showed that S. ellipticum leaves showed comparable activity to the 
positive control cisplatin. C. prostrata showed a 50% inhibition at 500 µg/ml while C. 
paniculatum, C. trigyna and D. cordata showed inhibition lower than 50% for all the 
concentrations tested.  
IC50 values of 88.60 ± 0.03 and 93.03 ± 0.03 μg/ml were obtained for S. ellipticum leaf 
extract against HeLa and MCF-7 cancer cells, respectively. This extract was also tested on 
PBMCs and Chang liver cells to determine its toxicity on normal cells. The extract had an 
IC50 of greater than 125 µg/ml against both proliferating and confluent Chang liver cells 
whereas the IC50 for PBMCs (77.66 μg/ml) was similar to that of the cancer cell lines.  These 
results point toward possible cell type selectivity of the extract but this needs to be confirmed 
by testing more cell types. 
 In an attempt to determine the active compound(s) within the plant leaf extract, five fractions 
(petroleum ether, butanol, aqueous, ethyl acetate and chloroform) were prepared and 
subjected to further screening against MCF-7 and confluent Chang liver cells to determine 
their degree of cytotoxicity. The most active fractions were those prepared in the solvents 
ethyl acetate (SEA) and chloroform (Scf), with polarity indices of 4.4 and 4.1, respectively.  
In comparison, the polarity index of water is 10.2 and that of the other two solvents used are 
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0.1 (petroleum ether) and 3.9 (butanol). This indicates that the active compounds have 
intermediate polarities.  Both fractions were more toxic to MCF-7 cells than confluent Chang 
liver cells, indicating possible antiproliferative effects. This result was more encouraging than 
the result for the crude extract which was much more toxic to the Chang liver cells. 
Of the five compounds that were isolated from the two active fractions of S. ellipticum, two 
of the ethyl acetate compounds were active against MCF-7 cells, one with an IC50 below 62.5 
μg/ml (SV2-2a, Table 4.5), and the other below 31 μg/ml (SV2-2b).  Unfortunately only a small 
amount of each compound was isolated for screening and after reconstitution in DMSO they 
both soon lost activity. Future studies could attempt re-isolation and stability testing under 
different conditions so that their structures can be elucidated and their activities investigated 
further.  The other three compounds were inactive or less active than SV2-2a and SV2-2b and 
did not warrant further investigation. The chloroform fraction was more active than the ethyl 
acetate fraction, yet no active compound could be isolated from it in this study.  Future work 
could involve isolation of more compounds from the chloroform fraction for screening. 
The crude S. ellipticum leaf extract induced cell cycle arrest in G1/G0 as well as G2/M phase 
in all three cell lines, with the most prominent effect being in HeLa and MCF-7 cells. This 
effect only became prominent after 24 hours and was more enhanced at 48 hours. These 
results suggest that the extract has a dual effect, most likely due to the presence of more than 
one active compound. It would be interesting to establish whether the two unstable isolated 
compounds, SV2-2a and SV2-2b, were responsible for this dual effect.   
The increase in the sub-G1 peak observed during cell cycle analysis after treatment with S. 
ellipticum leaf extract was not accompanied by PS translocation and thus could not be 
confirmed as apoptosis. However, a small increase in the percentage secondary necrotic cells 
(PI
+
 and Annexin V-FITC
+
) was seen, when compared to the control cells. This increase was 
too small to fully explain the percentage growth inhibition observed with the MTT assay.  
These results conclude that S. ellipticum does not cause apoptosis in the U937 cancer cells. It 
seems to have an antiproliferative effect through induction of cell cycle arrest rather than a 
cytotoxic effect.   
Possible antiproliferative mechanisms that could be investigated in future are; to establish 
whether the cell cycle was arrested in the G1 phase or if cells were forced to exit the cell 
cycle and remain in G0 and whether the G2/M arrest occurred in the G2 or M phase. By 
measuring the levels of CDK inhibitors (such as p21 or p27) and cyclins and/or measuring 
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the activities of specific cyclin-CDK complexes, it should be able to resolve these questions 
[21, 27, 28].  If the cells are found to be in the G0 phase, the possibility exists that the extract 
induces differentiation or senescence. The indication that the S. ellipticum extract reduced 
hTERT levels may further point towards the possibility of senescence in cells treated with 
this extract [79]. 
C. paniculatum showed more than 50% growth inhibitory activity against HeLa cells at 250 
µg/ml. During bio-assay guided fractionation, three fractions (aqueous, petroleum ether and 
ethyl acetate) were screened.  All three showed cytotoxic activity but the highest activity was 
obtained with the ethyl acetate fraction. The observation that three fractions with vastly 
different polarities were all active may indicate that the extract contains more than one active 
compound. 
Three compounds were isolated from the ethyl acetate fraction and subjected to further 
screening against HeLa, HT29 and MCF-7 cancer cells. The isolated compounds showed a 
dose-dependent cytotoxic effect. Two of them were identified by collaborators in China and 
the third, Cpe 4-9, was found to contain impurities. Cpe 4-9 had a cytotoxic effect lower than 
that of Cpe 4-4 (Pheophorbide a) and comparable to Cpe 3-4 (Pheophorbide a methyl ester), 
which then lead to the decision not to purify it further. Results from a cytotoxicity assay 
performed with PBMCs further suggest that the methyl ester was less toxic to normal cells 
than pheophorbide a. These two compounds were then used to establish whether they induced 
cell cycle arrest against HeLa cells. Results revealed that the two compounds act through 
induction of cell cycle arrest in G1/G0 phase. No increase was observed in the sub-G1 
(apoptotic) peak therefore it would appear that reduction in viable cell numbers compared to 
control cells are due to inhibition of proliferation rather than cytotoxicity. 
Numerous Combretum species have been illustrated to be cytotoxic to cancer cell lines in the 
past [145], but this was the first study done on C. paniculatum. The most well known and 
best studied species is C. caffrum from which the combretastatins A-1 and A-4 have been 
isolated. These compounds inhibit tubulin polymerisation and therefore prevent mitotic 
spindle formation at very low micromolar concentrations [145, 146].  It is possible that these 
compounds were present in the crude extract used in the present study although they were not 
isolated from the fractions. Future studies should investigate this possibility by further 
characterising the fractions obtained from the crude extract.  This was the first study to report 
on the cytotoxic activity of C. paniculatum. It was also the first to show that the two 
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compounds pheophytin a and its methyl ester were able to induce G1/G0 arrest which may 
contribute to the growth inhibition observed with the crude extract. The potent induction of 
growth arrest and the absence of toxicity of the methyl ester on PBMCs supports our 
suggestion that the compound is not cytotoxic but cytostatic. Apart from the two isolated 
compounds and possibly the combretastatins, many other compounds may contribute to the 
activity of the crude extract. Examples include tannins and flavonoids [145]. 
Since this study forms part of an ongoing collaboration two more plant extracts U. chamae 
and L. cupanioides leaf (LL) and root (LR) extracts were supplied for cytotoxic screening 
against HeLa, HT29 and MCF-7 cancer cells. No published work could be found on the 
anticancer potential of these two species and they were shown here, for the first time, to 
inhibit HeLa, MCF-7 and to a lesser extent, HT29 cell growth. It has been reported that the 
extracts of U. chamae has mutagenic effects and a cytotoxic tribenzylated flavanone named 
uvarinol, has been isolated from U. chamae [123]. It is possible that this compound was 
responsible for the activity observed in this study but this needs confirmation. 
L. cupanioides root extract (LR) showed very low inhibitory effect against all three cancer 
cell lines at both concentrations. The leaf extract (LL) showed more potential, especially 
against HeLa and MCF-7 cells. This extract was fractionated using water, butanol, ethyl 
acetate, hexane, chloroform and methanol and the ethyl acetate fraction was most active, 
again with higher activity against HeLa and MCF-7. Further investigation of this fraction was 
not within the scope of the present study. Polyphenolic compounds of the plant extract have 
been recognised and are well known to exhibit a number of biological activities of which an 
anticancer effect is one [144]. This could form the basis of further work on the ethyl acetate 
fraction in future. 
In summary, a total of 20 extracts from 18 plant species were screened for in vitro cytotoxic 
activity against cancer cell lines. Seven of these showed good potential achieving > 50% 
inhibition in one or more cell line at 125 μg/ml. Their IC50 values are therefore < 125 μg/ml, 
which can be considered a realistic and potentially useful concentration when moving on to in 
vivo models [143]. The relatively high percentage of extracts with positive results should not 
be surprising, considering that all these plants are used in Nigerian traditional medicine for 
the treatment of various types of cancer.  Two of the seven best extracts were followed up by 
other students. C. prostrata was shown to induce apoptosis via the extrinsic pathway, while 
L. cupaniodes leaf extract was found to induce G1/G0 arrest, followed by apoptosis. The 
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induction of cell cycle arrest was accompanied by an increase in the number of senescent 
cells.  The work from these two studies has not been published yet. 
Two extracts were followed up in the present study, namely S. ellipticum and C. paniculatum.  
Two active compounds were isolated from each of these extracts but only the C. paniculatum 
compounds could be identified as pheophorbide a and pheophorbide a methyl ester. This 
study further identified a number of extracts and/or fractions that were investigated by other 
students in our research group or can still be investigated in future. 
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